Methods of treatment using pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds

ABSTRACT

Compounds useful for the treatment of pain or cancer in a mammal.

CROSS-REFERENCE TO RELATED APPLICATION(S)

This application is a Divisional of U.S. application Ser. No.14/442,613, filed May 13, 2015, which is a 35 U.S.C. § 371 applicationof International Application No. PCT/US2013/069729, filed Nov. 12, 2013,which claims priority to U.S. Provisional Application No. 61/725,913,filed Nov. 13, 2012, which applications are herein incorporated byreference in their entirety.

BACKGROUND OF THE INVENTION

The present invention relates to novel compounds, to pharmaceuticalcompositions comprising the compounds, to processes for making thecompounds and to the use of the compounds in therapy. More particularly,it relates to pyrrolidinyl urea, thiourea, guanidine and cyanoguanidinecompounds which exhibit TrkA kinase inhibition, and which are useful inthe treatment of pain, cancer, inflammation/inflammatory diseases,neurodegenerative diseases, certain infectious diseases, Sjogren'ssyndrome, endometriosis, diabetic peripheral neuropathy, prostatitis orpelvic pain syndrome.

The current treatment regimens for pain conditions utilize severalclasses of compounds. The opioids (such as morphine) have severaldrawbacks including emetic, constipatory and negative respiratoryeffects, as well as the potential for addictions. Non-steroidalanti-inflammatory analgesics (NSAIDs, such as COX-1 or COX-2 types) alsohave drawbacks including insufficient efficacy in treating severe pain.In addition, COX-1 inhibitors can cause ulcers of the mucosa.Accordingly, there is a continuing need for new and more effectivetreatments for the relief of pain, especially chronic pain.

Trk's are the high affinity receptor tyrosine kinases activated by agroup of soluble growth factors called neurotrophins (NT). The Trkreceptor family has three members: TrkA, TrkB and TrkC. Among theneurotrophins are (i) nerve growth factor (NGF) which activates TrkA,(ii) brain-derived neurotrophic factor (BDNF) and NT-4/5 which activateTrkB and (iii) NT3 which activates TrkC. Trk's are widely expressed inneuronal tissue and are implicated in the maintenance, signaling andsurvival of neuronal cells (Patapoutian, A. et al., Current Opinion inNeurobiology, 2001, 11, 272-280).

Inhibitors of the Trk/neurotrophin pathway have been demonstrated to beeffective in numerous pre-clinical animal models of pain. For example,antagonistic NGF and TrkA antibodies such as RN-624 have been shown tobe efficacious in inflammatory and neuropathic pain animal models(Woolf, C. J. et al. (1994) Neuroscience 62, 327-331; Zahn, P. K. et al.(2004) J. Pain 5, 157-163; McMahon, S. B. et al., (1995) Nat. Med. 1,774-780; Ma, Q. P. and Woolf, C. J. (1997) NeuroReport 8, 807-810;Shelton, D. L. et al. (2005) Pain 116, 8-16; Delafoy, L. et al. (2003)Pain 105, 489-497; Lamb, K. et al. (2003) Neurogastroenterol. Motil. 15,355-361; Jaggar, S. I. et al. (1999) Br. J. Anaesth. 83, 442-448) andneuropathic pain animal models (Ramer, M. S. and Bisby, M. A. (1999)Eur. J. Neurosci. 11, 837-846; Ro, L. S. et al. (1999); Herzberg, U. etal., Pain 79, 265-274 (1997) Neuroreport 8, 1613-1618; Theodosiou, M. etal. (1999) Pain 81, 245-255; Li, L. et al. (2003) Mol. Cell. Neurosci.23, 232-250; Gwak, Y. S. et al. (2003) Neurosci. Lett. 336, 117-120).

It has also been shown that NGF secreted by tumor cells and tumorinvading macrophages directly stimulates TrkA located on peripheral painfibers. Using various tumor models in both mice and rats, it wasdemonstrated that neutralizing NGF with a monoclonal antibody inhibitscancer related pain to a degree similar or superior to the highesttolerated dose of morphine. Because TrkA kinase may serve as a mediatorof NGF driven biological responses, inhibitors of TrkA and/or other Trkkinases may provide an effective treatment for chronic pain states.

Recent literature has also shown that overexpression, activation,amplification and/or mutation of Trk kinases are associated with manycancers including neuroblastoma (Brodeur, G. M., Nat. Rev. Cancer 2003,3, 203-216), ovarian (Davidson. B., et al., Clin. Cancer Res. 2003, 9,2248-2259), colorectal cancer (Bardelli, A., Science 2003, 300, 949),melanoma (Truzzi, F., et al., Dermato-Endocrinology 2008, 3 (1), pp.32-36), head and neck cancer (Yilmaz, T., et al., Cancer Biology andTherapy 2010, 10 (6), pp. 644-653), gastric carcinoma (Du, J. et al.,World Journal of Gastroenterology 2003, 9 (7), pp. 1431-1434), lungcarcinoma (Ricci A., et al., American Journal of Respiratory Cell andMolecular Biology 25 (4), pp. 439-446), breast cancer (Jin, W., et al.,Carcinogenesis 2010, 31 (11), pp. 1939-1947), Glioblastoma (Wadhwa, S.,et al., Journal of Biosciences 2003, 28 (2), pp. 181-188),medulloblastoma (Gruber-Olipitz, M., et al., Journal of ProteomeResearch 2008, 7 (5), pp. 1932-1944), secratory breast cancer (Euthus,D. M., et al., Cancer Cell 2002, 2 (5), pp. 347-348), salivary glandcancer (Li, Y.-G., et al., Chinese Journal of Cancer Prevention andTreatment 2009, 16 (6), pp. 428-430), papillary thyroid carcinoma(Greco, A., et al., Molecular and Cellular Endocrinology 2010, 321 (1),pp. 44-49) and adult myeloid leukemia (Eguchi, M., et al., Blood 1999,93 (4), pp. 1355-1363). In preclinical models of cancer, non-selectivesmall molecule inhibitors of TrkA, B and C were efficacious in bothinhibiting tumor growth and stopping tumor metastasis (Nakagawara, A.(2001) Cancer Letters 169:107-114; Meyer, J. et al. (2007) Leukemia,1-10; Pierottia, M. A. and Greco A., (2006) Cancer Letters 232:90-98;Eric Adriaenssens, E., et al. Cancer Res (2008) 68:(2) 346-351).

In addition, inhibition of the neurotrophin/Trk pathway has been shownto be effective in treatment of pre-clinical models of inflammatorydiseases with NGF antibodies or non-selective small molecule inhibitorsof TrkA. For example, inhibition of the neurotrophin/Trk pathway hasbeen implicated in preclinical models of inflammatory lung diseasesincluding asthma (Freund-Michel, V; Frossard, N., Pharmacology &Therapeutics (2008) 117(1), 52-76), interstitial cystitis (Hu Vivian Y;et. al. The Journal of Urology (2005), 173(3), 1016-21), bladder painsyndrome (Liu, H.-T., et al., (2010) BJU International, 106 (11), pp.1681-1685), inflammatory bowel diseases including ulcerative colitis andCrohn's disease (Di Mola, F. F, et. al., Gut (2000) 46(5), 670-678) andinflammatory skin diseases such as atopic dermatitis (Dou, Y.-C., et.al. Archives of Dermatological Research (2006) 298(1), 31-37), eczemaand psoriasis (Raychaudhuri, S. P., et al., J Investigative Dermatology(2004) 122(3), 812-819).

The TrkA receptor is also thought to be critical to the disease processof the parasitic infection of Trypanosoma cruzi (Chagas disease) inhuman hosts (de Melo-Jorge, M. et al., Cell Host & Microbe (2007) 1(4),251-261).

Trk inhibitors may also find use in treating disease related to animbalance of the regulation of bone remodeling, such as osteoporosis,rheumatoid arthritis, and bone metastases. Bone metastases are afrequent complication of cancer, occurring in up to 70 percent ofpatients with advanced breast or prostate cancer and in approximately 15to 30 percent of patients with carcinoma of the lung, colon, stomach,bladder, uterus, rectum, thyroid, or kidney. Osteolytic metastases cancause severe pain, pathologic fractures, life-threatening hypercalcemia,spinal cord compression, and other nerve-compression syndromes. Forthese reasons, bone metastasis is a serious and costly complication ofcancer. Therefore, agents that can induce apoptosis of proliferatingosteoblasts would be highly advantageous. Expression of TrkA receptorshas been observed in the bone-forming area in mouse models of bonefracture (K. Asaumi, et al., Bone (2000) 26(6) 625-633). In addition,localization of NGF was observed in almost all bone-forming cells (K.Asaumi, et al.). Recently, it was demonstrated that a Trk inhibitorinhibits the signaling activated by neurotrophins binding to all threeof the Trk receptors in human hFOB osteoblasts (J. Pinski, et al.,(2002) 62, 986-989). These data support the rationale for the use of Trkinhibitors for the treatment of bone remodeling diseases, such as bonemetastases in cancer patients.

Trk inhibitors may also find use in treating diseases and disorders suchas Sjogren's syndrome (Fauchais, A. L., et al., (2009) ScandinavianJournal of Rheumatology, 38(1), pp. 50-57), endometriosis (Barcena DeArellano, M. L., et al., (2011) Reproductive Sciences, 18(12), pp.1202-1210; Barcena De Arellano, et al., (2011) Fertility and Sterility,95(3), pp. 1123-1126; Cattaneo, A., (2010) Current Opinion in MolecularTherapeutics, 12(1), pp. 94-106), diabetic peripheral neuropathy (Kim,H. C., et al., (2009) Diabetic Medicine, 26 (12), pp. 1228-1234;Siniscalco, D., et al., (2011) Current Neuropharmacology, 9(4), pp.523-529; Ossipov, M. H., (2011) Current Pain and Headache Reports,15(3), pp. 185-192), and prostatitis and pelvic pain syndrome (Watanabe,T., et al., (2011) BJU International, 108(2), pp. 248-251; and Miller,L. J., et al., (2002) Urology, 59(4), pp. 603-608).

Several classes of small molecule inhibitors of Trk kinases said to beuseful for treating pain or cancer are known (Expert Opin. Ther. Patents(2009) 19(3), 305-319).

International application publication WO 2010/032856 describes compoundsrepresented by the formula

wherein ring B is an aromatic ring, ring D is an aromatic ring, and L isNR³, NR³C(R^(4a)R^(4b)), O or OC(R^(4a)R^(4b)), which are asserted to betachykinin receptor antagonists.

SUMMARY OF THE INVENTION

It has now been found that pyrrolidinyl urea, thiourea, guanidine andcyanoguanidine compounds are inhibitors of TrkA, and useful for treatingdisorders and diseases such as pain, including chronic and acute pain.Compounds of the invention useful in the treatment of multiple types ofpain including inflammatory pain, neuropathic pain, and pain associatedwith cancer, surgery, or bone fracture. In addition, compounds of theinvention are useful for treating cancer, inflammation or inflammatorydiseases, neurodegenerative diseases, certain infectious diseases,Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy,prostatitis or pelvic pain syndrome, and diseases related to animbalance of the regulation of bone remodeling, such as osteoporosis,rheumatoid arthritis, and bone metastases.

More specifically, provided herein are compounds of Formula I:

or stereoisomers, tautomers, or pharmaceutically acceptable salts,solvates or prodrugs thereof, wherein Ring B and the NH—C(═X)—NH moietyare in the trans configuration and R¹, R², R^(a), R^(b), R^(c), R^(d),X, Ring B and Ring C are as defined herein.

Another aspect of the present invention provides methods of treating adisease or disorder modulated by TrkA, comprising administering to amammal in need of such treatment an effective amount of a compound ofthis invention or a stereoisomer, solvate or pharmaceutically acceptablesalt thereof. In one embodiment, the disease and disorders includechronic and acute pain, including but not limited to inflammatory pain,neuropathic pain, and pain associated with cancer, surgery, or bonefracture. In another embodiment, the disease and disorders include, butare not limited to, cancer, inflammation or inflammatory diseases,neurodegenerative diseases, certain infectious diseases, Sjogren'ssyndrome, endometriosis, diabetic peripheral neuropathy, prostatitis orpelvic pain syndrome, and diseases related to an imbalance of theregulation of bone remodeling, such as osteoporosis, rheumatoidarthritis, and bone metastases. In one embodiment, the treatmentincludes treating the mammal with a compound of this invention incombination with an additional therapeutic agent.

Another aspect of the present invention provides a pharmaceuticalcomposition comprising a compound of the present invention or apharmaceutically acceptable salt thereof. Another aspect of the presentinvention provides the compounds of the present invention for use intherapy.

Another aspect of the present invention provides the compounds of thepresent invention for use in the treatment of disease and disorders suchas chronic and acute pain, including but not limited to inflammatorypain, neuropathic pain, and pain associated with cancer, surgery, orbone fracture. Another aspect of the present invention provides thecompounds of the present invention for use in the treatment of diseaseand disorders selected from cancer, inflammation or inflammatorydiseases, neurodegenerative diseases, certain infectious diseases,Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy,prostatitis or pelvic pain syndrome, and diseases related to animbalance of the regulation of bone remodeling, such as osteoporosis,rheumatoid arthritis, and bone metastases.

Another aspect of the present invention provides the use of a compoundof this invention in the manufacture of a medicament for the treatmentof disease and disorders such as chronic and acute pain including, butnot limited to, inflammatory pain, neuropathic pain, and pain associatedwith cancer, surgery, or bone fracture.

Another aspect of the present invention provides the use of a compoundof this invention in the manufacture of a medicament for the treatmentof disease and disorders selected from cancer, inflammation orinflammatory diseases, neurodegenerative diseases, certain infectiousdiseases, Sjogren's syndrome, endometriosis, diabetic peripheralneuropathy, prostatitis or pelvic pain syndrome, and diseases related toan imbalance of the regulation of bone remodeling, such as osteoporosis,rheumatoid arthritis, and bone metastases.

Another aspect of the present invention provides intermediates forpreparing compounds of Formula I.

Another aspect of the present invention includes methods of preparing,methods of separation, and methods of purification of the compounds ofthis invention.

DETAILED DESCRIPTION OF THE INVENTION

Provided herein are compounds, and pharmaceutical formulations thereof,that are useful in the treatment of diseases, conditions and/ordisorders modulated by TrkA.

A representative compound of the invention (See Table B below), wasfound to be highly selective for TrkA over a panel of about 230 otherkinases at 10 μM concentration. In addition, compounds of the inventionsuch as those shown in Table A below, were found to be at least1000-fold more selective for TrkA versus p38α.

One embodiment provides a compound of Formula I:

or stereoisomers, tautomers, or pharmaceutically acceptable salts,solvates or prodrugs thereof, wherein:Ring B and the NH—C(═X)—NH moiety are in the trans configuration;R^(a), R^(b), R^(c) and R^(d) are independently selected from H and(1-3C)alkyl,or R^(c) and R^(d) are independently selected from H and (1-3C)alkyl,and R^(a) and R^(b) together with the atom to which they are attachedform a cyclopropyl ring;

X is O, S, NH, or N—CN;

R¹ is (1-3C alkoxy)(1-6C)alkyl, (trifluoromethoxy)(1-6C)alkyl, (1-3Csulfanyl)(1-6C)alkyl, monofluoro(1-6C)alkyl, difluoro(1-6C)alkyl,trifluoro(1-6C)alkyl, tetrafluoro(2-6C)alkyl, pentafluro(2-6C)alkyl,cyano(1-6C)alkyl, aminocarbonyl(1-6C)alkyl, hydroxy(1-6C)alkyl,dihydroxy(2-6C)alkyl, (1-6C)alkyl, (1-3C alkylamino)(1-3C)alkyl, (1-4Calkoxycarbonyl)(1-6C)alkyl, amino(1-6C)alkyl, hydroxyl(1-3Calkoxy)(1-6C)alkyl, di(1-3C alkoxy)(1-6C)alkyl, (1-3Calkoxy)trifluoro(1-6C)alkyl, hydroxytrifluoro(1-6C)alkyl, (1-4Calkoxycarbonyl)(1-3C alkoxy)(1-6C)alkyl or hydroxycarbonyl(1-3Calkoxy)(1-6C)alkyl;

R² is H, F, or OH;

Ring B is Ar¹ or hetAr¹;Ar¹ is phenyl optionally substituted with one or more substituentsindependently selected from halogen, CF₃, CF₃O—, (1-4C)alkoxy,hydroxy(1-4C)alkyl, (1-6C)alkyl and CN;hetAr¹ is a 5-6 membered heteroaryl having 1-3 ring heteroatomsindependently selected from N, S and O, and optionally substituted withone or more substituents independently selected from (1-6C)alkyl,halogen, OH, CF₃, NH₂ and hydroxy(1-2C)alkyl; Ring C is

R³ is H, (1-6C)alkyl, hydroxy(1-6C)alkyl, Ar², hetCyc¹,(3-7C)cycloalkyl, hetAr², or a C5-C8 bridged carbocyclic ring;Ar² is phenyl optionally substituted with one or more substituentsindependently selected from halogen and (1-6C)alkyl;hetCyc¹ is a 5-6-membered saturated or partially unsaturatedheterocyclic ring having 1-2 ring heteroatoms independently selectedfrom N and O;hetAr² is a 5-6 membered heteroaryl ring having 1-3 ring heteroatomsindependently selected from N, O and S and optionally substituted withone or more substituents independently selected from (1-6C)alkyl andhalogen;R⁴ is selected from (1-6C alkyl)SO₂—, (1-6C alkyl)C(═O)— and from thestructures:

R^(m) is (1-3C)alkyl substituted with 1-3 fluoros, or (3-4C)cycloalkyl;

R^(n) is (1-3C)alkyl;

R^(q) is (1-3C)alkyl optionally substituted with 1-3 fluoros;R^(x) is (1-6C)alkyl, halogen, CN, hydroxy(1-6C)alkyl,trifluoro(1-6C)alkyl, (3-6C)cycloalkyl, (3-6C cycloalkyl)CH₂—, (3-6Ccycloalkyl)C(═O)—, (1-3C alkoxy)(1-6C)alkyl, (1-6C)alkoxy,(1-6C)alkylsulfonyl, NH₂, (1-6C alkyl)amino, di(1-6C alkyl)amino, ortrifluoro(1-3C)alkoxy;n is 0, 1, 2, 3 or 4;m is 0, 1, 2 or 3;R^(y) is F or (1-3C)alkyl optionally substituted with 1-3 fluoros;p is 0, 1 or 2;R^(z) is (3-4C)cycloalkyl, or (1-3C)alkyl optionally substituted with1-3 fluoros; andR⁵ is H, (1-6C)alkyl, monofluoro(1-6C)alkyl, difluoro(1-6C)alkyl,trifluoro(1-6C)alkyl, tetrafluoro(2-6C)alkyl, pentafluoro(2-6C)alkyl,halogen, CN, (1-4C)alkoxy, hydroxy(1-4C)alkyl, (1-3C alkoxy)(1-4C)alkyl,(1-4C alkyl)OC(═O)—, (1-6C)alkylsulfanyl, phenyl [optionally substitutedwith one or more substituents independently selected from halogen,(1-6C)alkyl and (1-6C)alkoxy], (3-4C)cycloalkyl, amino, aminocarbonyl,or trifluoro(1-3C alkyl)amido.In one embodiment, compounds of Formula I include compounds where R⁴ isother than (1-6C alkyl)SO₂— and (1-6C alkyl)C(═O)—.

It is to be understood that in instances where two or more radicals areused in succession to define a substituent attached to a structure, thefirst named radical is considered to be terminal and the last namedradical is considered to be attached to the structure in question. Thus,for example, the radical “alkoxyalkyl” is attached to the structure inquestion by the alkyl group.

The terms “(1-6C)alkyl”, “(1-4C)alkyl” and “(1-3C)alkyl” as used hereinrefer to saturated linear monovalent hydrocarbon radicals of one to sixcarbon atoms, one to four carbon atoms, and one to three carbon atoms,respectively, or a branched saturated monovalent hydrocarbon radical ofthree to six carbon atoms, three to four carbon atoms, or three carbonatoms, respectively. Examples include, but are not limited to, methyl,ethyl, 1-propyl, 2-propyl, 1-butyl, 2-methyl-1-propyl, 2-butyl,2-methyl-2-propyl, 2,2-dimethylpropyl, 1-pentyl, 2-pentyl, 3-pentyl,2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl,1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl,4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl,2,3-dimethyl-2-butyl, and 3,3-dimethyl-2-butyl.

“(1-6C)Alkylsulfanyl” as used herein refers to a (1-6C alkyl)S— group,wherein the radical is on the sulfur atom and the (1-6C alkyl) portionis as defined above. Examples include methylsulfanyl (CH₃S—) andethylsulfanyl (CH₂CH₂S—).“(1-4C)Alkoxy”, “(1-3C)alkoxy” and “(1-6C)alkoxy” refer to an OR radicalwhere R is (1-4C)alkyl, (1-3C)alkyl, (1-6C)alkyl, or (2-6C)alkyl,respectively, as defined above. Examples include methoxy, ethoxy, andthe like.“(1-4C Alkoxycarbonyl)(1-6C)alkyl” means a (1-6C)alkyl group as definedherein, wherein one of the carbons is substituted with a (1-4Calkoxy)carbonyl group as defined herein.“(1-3C Alkoxy)trifluoro(1-6C)alkyl” means a (1-6C)alkyl group as definedherein, wherein one of the carbons is substituted with three fluoros,and another carbon is substituted with a (1-3C)alkoxy group as definedherein.“(1-4C Alkoxycarbonyl)(1-3C alkoxy)(1-6C)alkyl” means a (1-3Calkoxy)(1-6C)alkyl group as defined herein wherein one of the carbonatoms is substituted with one (1-4C alkoxycarbonyl group, i.e., analkyl-O—C(═O)— group.

“Amino” means a —NRR′ group where R and R′ are independently selectedfrom hydrogen or (1-3C)alkyl as defined herein. Examples include H₂N—,CH₃NH—, (CH₃)₂N, and the like.

“Amino(1-6C)alkyl” means a linear saturated monovalent hydrocarbonradical of one to six carbon atoms or a branched saturated monovalenthydrocarbon radical of three to six carbon atoms, wherein one of thecarbon atoms is substituted with one —NRR′ group where R and R′ areindependently selected from hydrogen or (1-3C)alkyl as defined herein.Examples include aminomethyl, methylaminoethyl,2-ethylamino-2-methylethyl, and the like.

“Aminocarbonyl” means a RR′NCO— radical where R and R′ are independentlyhydrogen or (1-6C)alkyl as defined herein. Examples include H₂NCO—,dimethylaminocarbonyl, and the like.

“Aminocarbonyl(1-6C)alkyl” means a linear saturated hydrocarbon radicalof one to six carbon atoms or a branched saturated monovalenthydrocarbon radical of three to six carbons wherein one of the carbonatoms is substituted with one aminocarbonyl group as defined herein,e.g., 2-aminocarbonylethyl, 1-, 2-, or 3-dimethylaminocarbonylpropyl,and the like.

“Hydroxycarbonyl” means HOC(═O)—.

“Cyano(1-6C)alkyl” means a linear saturated hydrocarbon radical of oneto six carbon atoms or a branched saturated monovalent hydrocarbonradical of three to six carbons substituted with a cyano (CN) group.

“(3-6C)Cycloalkyl” means a cyclic saturated monovalent hydrocarbonradical of three to six carbon atoms, e.g., cyclopropyl, cyclobutyl,cyclopentyl, or cyclohexyl.

“Di(1-3C alkoxy)(1-6C)alkyl” means a (1-6C)alkyl group as definedherein, wherein two carbons are each substituted with one (1-3C)alkoxygroup as defined herein.

“Dihydroxy(2-6C)alkyl” means a linear saturated hydrocarbon radical oftwo to six carbon atoms or a branched saturated monovalent hydrocarbonradical of three to six carbons substituted with two hydroxy (OH)groups, provided that two hydroxy groups are not both on the same carbonatom. “Halogen” as used herein means F, Cl, Br or I.

“Heterocycle” refers to a saturated or partially unsaturated ring systemhaving one or more ring heteroatoms as recited for the specificheterocyclic group, wherein the heterocycle is optionally substitutedwith substituents as defined for that particular heterocyclic group.

“Heteroaryl” refers to a 5-6 membered unsaturated ring system having oneor more ring heteroatoms as recited for the specific heteroaryl group,wherein the heteroaryl is optionally substituted with substituents asdefined for that particular heteroaryl group.

“Hydroxy(1-6C)alkyl” and “hydroxy(1-4C)alkyl” means a linear saturatedhydrocarbon radical of one to six carbon atoms or one to four carbonatoms, respectively, or a branched saturated monovalent hydrocarbonradical of three to six carbon atoms or three to four carbon atoms,respectively, wherein one of the carbon atoms is substituted with ahydroxy (OH) group.

“Hydroxy(1-3C alkoxy)(1-6C)alkyl” means a (1-3C alkoxy)(1-6C)alkyl groupas defined herein, wherein one of the carbons is substituted with ahydroxy group.

“Monofluoro(1-6C)alkyl”, “difluoro(1-6C)alkyl” and“trifluoro(1-6C)alkyl” refer to a (1-6C)alkyl group as defined hereinwherein one to three hydrogen atoms, respectively, is replaced by afluoro group.

“Tetrafluoro(2-6C)alkyl” and “pentafluoro(2-6C)alkyl” refer to a linearsaturated monovalent hydrocarbon radical of two to six carbon atoms or abranched saturated monovalent hydrocarbon radical of three to six carbonatoms wherein four to five hydrogen atoms, respectively, is replaced bya fluoro group.

“(Trifluoromethoxy)(1-6C)alkyl” means a linear saturated hydrocarbonradical of one to six carbon atoms substituted with one CF₃O— group.

“Trifluoro(1-3C alkyl)amido” means a (1-3C alkyl)C(═O)NH— group whereinone of the carbons is substituted with three fluoros.

“Trifluoro(1-3C)alkoxy” means a (1-3C)alkoxy group as defined herein,wherein one of the carbon atoms is substituted with three fluoros.

(1-3C Sulfanyl)(1-6C)alkyl” means a linear saturated hydrocarbon radicalof one to six carbon atoms substituted with one (1-3C)S— group.

It should be noted that compounds of the invention may contain groupsthat may exist in tautomeric forms, such as heteroatom substitutedheteroaryl or heterocyclic groups and the like, which are illustrated inthe following general and specific examples:

where Y′═O, S, or NR, and though one form is named, described, displayedand/or claimed herein, all the tautomeric forms are intended to beinherently included in such name, description, display and/or claim.

In one embodiment of Formula I, R^(a), R^(b), R^(c) and R^(d) areindependently selected from H and methyl. In one embodiment, R^(a),R^(b), R^(c) and R^(d) are hydrogen. In one embodiment, R^(a) is methyland R^(b), R^(c) and R^(d) are hydrogen. In one embodiment, R^(a) andR^(b) are methyl and R^(c) and R^(d) are hydrogen. In one embodiment,R^(a), R^(b) and R^(c) are hydrogen and R^(d) is methyl. In oneembodiment, R^(a) and R^(b) are hydrogen and R^(c) and R^(d) are methyl.

In one embodiment, R^(c) and R^(d) are independently selected from H and(1-3C)alkyl, and R^(a) and R^(b) together with the atom to which theyare attached form a cyclopropyl ring.

In one embodiment, X is O.

In one embodiment, X is S.

In one embodiment, X is NH.

In one embodiment, X is N—CN.

In one embodiment, R¹ is (1-3C alkoxy)(1-6C)alkyl, for example,methoxyethyl, methoxypropyl, ethoxyethyl and 2-methoxypropyl. Particularexamples include 2-methoxyethyl and 2-methoxypropyl having thestructures:

In one embodiment, R¹ is 2-methoxyethyl.

In one embodiment, R¹ is (trifluoromethoxy)(1-6C)alkyl, for example,(trifluoromethoxy)ethyl, (trifluoromethoxy)propyl, and the like. In oneembodiment, R¹ is (trifluoromethoxy)ethyl.

In one embodiment, R¹ is (1-3C sulfanyl)(1-6C)alkyl, for examplemethylsulfanylethyl, ethylsulfanylethyl, and the like. In oneembodiment, R¹ is methylsulfanylethyl.

In one embodiment, R¹ is monofluoro(1-6C)alkyl, difluoro(1-6C)alkyl ortrifluoro(1-6C)alkyl. In one embodiment, R¹ is 1,3-difluoroprop-2-yl,2,2-difluoroethyl, 4,4,4-trifluorobutyl or 2,2,2-trifluoroethyl havingthe structures:

In one embodiment, R¹ is tetrafluoro(2-6C)alkyl orpentafluoro(2-6C)alkyl. In one embodiment, R¹ is3,3,4,4,4-pentafluorobutyl.

In one embodiment, R¹ is cyano(1-6C)alkyl. In one embodiment, R¹ is2-cyanoethyl.

In one embodiment, R¹ is aminocarbonyl(1-6C)alkyl. In one embodiment, R¹is aminocarbonylmethyl. In one embodiment, R¹ ismethylaminocarbonylmethyl having the formula MeNHC(═O)CH₂—.

In one embodiment, R¹ is hydroxy(1-6C)alkyl. In one embodiment, R¹ is2-hydroxyethyl or 2-hydroxypropyl.

In one embodiment, R¹ is dihydroxy(2-6C)alkyl. In one embodiment, R¹ isthe structure:

In one embodiment, R¹ is (1-6C)alkyl. In one embodiment, R¹ is methyl,ethyl, or propyl.

In one embodiment, R¹ is (1-3C alkylamino)(1-3C)alkyl, that is, a(1-3C)alkyl group which is substituted with a (1-3C alkyl)amino group,for example a (1-3C alkyl)NH— group such as methylamino. In oneembodiment, R¹ is (2-methylamino)ethyl.

In one embodiment, R¹ is (1-4C alkoxycarbonyl)(1-6C)alkyl. In oneembodiment, R¹ is methoxycarbonylmethyl, having the structure:

In one embodiment, R¹ is amino(1-6C)alkyl, such asmethylamino(1-6C)alkyl. In one embodiment, R¹ is 2-methylaminoethyl.

In one embodiment, R¹ is hydroxy(1-3C alkoxy)(1-6C)alkyl. Examplesinclude hydroxymethoxy(1-6C)alkyl. In one embodiment, R¹ is selectedfrom the structures:

In one embodiment, R¹ is di(1-3C alkoxy)(1-6C)alkyl. Examples includedimethoxy(1-6C)alkyl. In one embodiment, R¹ is 1,3-dimethoxyprop-2-ylhaving the structure:

In one embodiment, R¹ is (1-3C alkoxy)trifluoro(1-6C)alkyl. Examplesinclude methoxytrifluoro(1-6C)alkyl. In one embodiment, R¹ is3,3,3-trifluoro-2-methoxypropyl. In one embodiment, R¹ ishydroxytrifluoro(1-6C)alkyl. In one embodiment, R¹ is3,3,3-trifluoro-2-hydroxypropyl.

In one embodiment, R¹ is (1-4C alkoxycarbonyl)(1-3C alkoxy)(1-6C)alkyl.Examples include (methoxycarbonyl)methoxy(1-6C)alkyl. In one embodiment,R¹ is a group having the structure:

In one embodiment, R¹ is hydroxycarbonyl(1-3C alkoxy)(1-6C)alkyl.Examples include (methoxycarbonyl)hydroxy(1-6C)alkyl. In one embodiment,R¹ is a group having the structure:

In one embodiment, R¹ is selected from (1-3C alkoxy)(1-6C)alkyl,difluoro(1-6C)alkyl and trifluoro(1-6C)alkyl.

In one embodiment, R² is H.

In one embodiment, R² is F.

In one embodiment, R² is OH.

In one embodiment of Formula I, Ring B is is Ar¹, where Ar¹ is phenyloptionally substituted with one or more substituents independentlyselected from halogen, CF₃, CF₃O—, (1-4C)alkoxy, hydroxy(1-4C)alkyl,(1-6C)alkyl, and CN. In one embodiment, Ar¹ is phenyl optionallysubstituted with one or more substituents independently selected fromhalogen, CF₃, (1-4C)alkoxy and CN. In one embodiment, Ar¹ is phenyloptionally substituted with one or more substituents independentlyselected from F, Cl, CF₃, MeO and CN.

In one embodiment, Ring B when represented by Ar¹ is selected fromphenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl,3,4-difluorophenyl, 3,5-difluorophenyl, 2,4-difluorophenyl,2,5-difluorophenyl, 3,4,5-trifluorophenyl, 2-chlorophenyl,3-chlorophenyl, 4-chlorophenyl, 3-trifluoromethylphenyl 3-methoxyphenyl,3-chloro-4-fluorophenyl, 4-chloro-3-fluorophenyl,3-chloro-5-fluorophenyl, 3-cyano-5-fluorophenyl, 2-cyanophenyl,4-cyanophenyl and 3-cyano-4-fluorophenyl.

In one embodiment, Ring B is is Ar¹, wherein Ar¹ is phenyl optionallysubstituted with one or more halogens. In one embodiment, Ar¹ is phenyloptionally substituted with one or more F or Cl. In one embodiment, Ar¹is 3-fluorophenyl, 4-fluorophenyl, 3,4-difluorophenyl,3,5-difluorophenyl, 3,4,5-trifluorophenyl, 3-chlorophenyl,3-chloro-4-fluorophenyl, 3-chloro-5-fluorophenyl, or4-chloro-3-fluorophenyl.

In one embodiment of Formula I, Ring B is hetAr¹, where hetAr¹ is a 5-6membered heteroaryl having 1-3 ring heteroatoms independently selectedfrom N, S and O, and is optionally substituted with one or moresubstituents independently selected from (1-6C)alkyl, halogen, OH, CF₃,NH₂ and hydroxy(1-2C)alkyl. In one embodiment, Ring B is hetAr¹, whereinhetAr¹ is a 5-6 membered heteroaryl having 1-2 ring heteroatomsindependently selected from N, S and O, and optionally substituted with1-2 groups independently selected from (1-6C)alkyl, halogen, OH, CF₃,NH₂ and hydroxy(1-2C)alkyl. Examples of Ring B include pyridyl,thiophenyl, thiazolyl, oxazolyl, and isoxazolyl rings optionallysubstituted with 1-2 groups independently selected from (1-6C)alkyl,halogen, OH, CF₃, NH₂ and hydroxy(1-2C)alkyl. In one embodiment, Ring Bis a pyridyl, thiophenyl, thiazolyl, oxazolyl, or isoxazolyl ringoptionally substituted with 1-2 groups independently selected fromhalogen and (1-6C)alkyl.

In one embodiment, Ring B when represented by hetAr¹ is selected frompyrid-4-yl, pyrid-3-yl, pyrid-2-yl, 5-fluoropyrid-3-yl, thien-2-yl,thiazol-2-yl, 2,4-dimethylthiazol-5-yl, oxazol-5-yl, isoxazol-5-yl,5-chloropyrid-3-yl, 5-fluoropyrid-2-yl, 3-fluoropyrid-4-yl and1-methylpyrazol-4-yl having the structures:

In one embodiment Ring B is a pyridyl ring optionally substituted with1-2 groups independently selected from (1-6C)alkyl and halogen.

Reference will now be made to Ring C:

In one embodiment, R³ is H.

In one embodiment, R³ is (1-6C)alkyl. In one embodiment, R³ is methyl orethyl.

In one embodiment, R³ is hydroxy(1-6C)alkyl. In one embodiment, R³ is2-hydroxyethyl.

In one embodiment, R³ is Ar², where Ar² is phenyl optionally substitutedwith one or more substituents independently selected from halogen and(1-6C)alkyl. In one embodiment, R³ is phenyl, 2-fluorophenyl,3-fluorophenyl, 4-fluorophenyl, 2-methylphenyl, 3-methylphenyl,4-methylphenyl, 3-(hydroxymethyl)phenyl, 3-chlorophenyl,3-chloro-4-fluorophenyl and 3-chloro-2-fluorophenyl. Particular examplesof R³ when represented by Ar² include phenyl, 2-fluorophenyl,3-fluorophenyl, 4-fluorophenyl, 2-methylphenyl, 3-methylphenyl and4-methylphenyl.

In one embodiment, R³ is phenyl.

In one embodiment, R³ is hetCyc¹, where hetCyc¹ is a 5-6-memberedsaturated or partially unsaturated heterocyclic ring having 1-2 ringheteroatoms independently selected from N and O. In one embodiment, R³is a pyrrolidinyl, tetrahydrofuranyl, imidazolidinyl, piperidinyl,piperazinyl, tetrahydropyranyl, or morpholinyl ring. In one embodiment,R³ is tetrahydro-2H-pyran-4-yl.

In one embodiment, R³ is (3-7C)cycloalkyl. In one embodiment R³ iscyclohexyl.

In one embodiment, R³ is hetAr², where hetAr² is 5-6 membered heteroarylring having 1-3 ring heteroatoms independently selected from N, O and Sand optionally substituted with one or more substituents independentlyselected from (1-6C)alkyl and halogen. In one embodiment, R³ is athienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl,oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, pyridyl,pyrimidyl, pyrazinyl, or pyridazinyl optionally substituted with one ormore substituents independently selected from (1-6C)alkyl and halogen.In one embodiment, R³ is pyrazolyl, pyridyl or pyridazinyl optionallysubstituted with one or more substituents independently selected from(1-6C)alkyl and halogen. In one embodiment, R³ is1-methyl-1H-pyrazol-4-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl,pyridazinyl or 3-chloropyrid-5-yl.

In one embodiment, R³ is a C5-C8 bridged carbocyclic ring. An exampleincludes the structure:

In one embodiment, R³ is selected from Ar², hetAr² and (1-6C)alkyl.

In one embodiment, R³ is selected from Ar² and hetAr².

In one embodiment, R³ is selected from Ar².

In one embodiment of Formula I, R⁴ is selected from (1-6C alkyl)SO₂—,(1-6C alkyl)C(═O)— and from the structures:

where R^(m), R^(q), R^(y), R^(z), and p are as defined for Formula I.

In one embodiment of Formula I, R⁴ is selected from (1-6C alkyl)SO₂— and(1-6C alkyl)C(═O)—.

In one embodiment of Formula I, R⁴ is (1-6C alkyl)SO₂—. In oneembodiment, R^(4 is CH) ₃SO₂—.

In one embodiment of Formula I, R⁴ is (1-6C alkyl)C(═O)—. In oneembodiment, R⁴ is CH₃C(═O)—.

In one embodiment of Formula I, R⁴ is selected from the structures:

where R^(m), R^(q), R^(y), R^(z), and p are as defined for Formula I.

In one embodiment of Formula I, R⁴ is

where R^(m), R^(y) and p are as defined for Formula I. In oneembodiment, p is 0. In one embodiment, p is 1. In one embodiment, R⁴ hasthe structure:

In one embodiment of Formula I, R⁴ is

where R^(z), R^(y) and p are as defined for Formula I. In oneembodiment, R^(z) is (1-3C)alkyl. In one embodiment, R^(z) is methyl. Inone embodiment, R^(z) is (1-3C)alkyl substituted with 1-3 fluoros. Inone embodiment, R^(z) is CF₃. In one embodiment, R^(z) is cyclopropyl orcyclobutyl. In one embodiment, p is 0. In one embodiment, p is 1. In oneembodiment, R⁴ has the structure:

In one embodiment of Formula I, R⁴ is

where R^(z), R^(y) and p are as defined for Formula I. In oneembodiment, R^(z) is (1-3C)alkyl. In one embodiment, R^(z) is methyl. Inone embodiment, R^(z) is (1-3C)alkyl substituted with 1-3 fluoros. Inone embodiment, R^(z) is CF₃. In one embodiment, R^(z) is cyclopropyl orcyclobutyl. In one embodiment, p is 0. In one embodiment, p is 1.

In one embodiment of Formula I, R⁴ is

where R^(z), R^(y) and p are as defined for Formula I. In oneembodiment, R^(z) is (1-3C)alkyl. In one embodiment, R^(z) is methyl. Inone embodiment, R^(z) is (1-3C)alkyl substituted with 1-3 fluoros. Inone embodiment, R^(z) is CF₃. In one embodiment, R^(z) is cyclopropyl orcyclobutyl. In one embodiment, p is 0. In one embodiment, p is 1.

In one embodiment of Formula I, R⁴ is

where R^(z), R^(y) and p are as defined for Formula I. In oneembodiment, R^(z) is (1-3C)alkyl. In one embodiment, R^(z) is methyl. Inone embodiment, R^(z) is (1-3C)alkyl substituted with 1-3 fluoros. Inone embodiment, R^(z) is CF₃. In one embodiment, R^(z) is cyclopropyl orcyclobutyl. In one embodiment, p is 0. In one embodiment, p is 1.

In one embodiment of Formula I, R⁴ is selected from the structures:

where R^(q), R^(y) and p are as defined for Formula I. In oneembodiment, R^(q) is (1-3C)alkyl. In one embodiment, R^(q) is methyl. Inone embodiment, R^(q) is (1-3C)alkyl substituted with 1-3 fluoros. Inone embodiment, R^(q) is CF₃. In one embodiment, p is 0. In oneembodiment, p is 1.In one embodiment of Formula I, R⁴ is selected from the structures:

where R^(q), R^(y) and p are as defined for Formula I. In oneembodiment, R^(q) is (1-3C)alkyl. In one embodiment, R^(q) is methyl. Inone embodiment, R^(q) is (1-3C)alkyl substituted with 1-3 fluoros. Inone embodiment, R^(q) is CF₃. In one embodiment, p is 0. In oneembodiment, p is 1.

In one embodiment of Formula I, R⁴ is selected from the structures:

where R^(n), R^(q), R^(x), Ry, n and m are as defined for Formula I.

In one embodiment, R^(q) is (1-3C)alkyl. In one embodiment, R^(q) ismethyl. In one embodiment, R^(q) is (1-3C)alkyl substituted with 1-3fluoros. In one embodiment, R^(q) is CF₃.

In one embodiment, R^(x) is fluoro, methyl, ethyl, methoxy, ethoxy,cyano or cyclopropyl.

In one embodiment, n is 0 or 1.

In one embodiment, m is 0 or 1.

In one embodiment of Formula I, R⁴ is selected from the followingstructures:

In one embodiment, R⁵ is H.

In one embodiment, R⁵ is (1-6C)alkyl. In one embodiment, R⁵ is methyl,ethyl, propyl, isopropyl or butyl. In one embodiment, R⁵ is methyl.

In one embodiment, R⁵ is monofluoro(1-6C)alkyl, difluoro(1-6C)alkyl,trifluoro(1-6C)alkyl, tetrafluro(2-6C)alkyl or pentafluro(2-6C)alkyl. Inone embodiment, R⁵ is fluoromethyl, 2-fluoroethyl, difluoromethyl,2,2-difluoroethyl, 1,3-difluoroprop-2-yl, trifluoromethyl,2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 1,1,2,2-tetrafluoropropylor 2,2,3,3,3-pentafluoropropyl.

In one embodiment, R⁵ is halogen. In one embodiment, R⁵ is F. In oneembodiment, R⁵ is Cl. In one embodiment, R⁵ is Br.

In one embodiment, R⁵ is CN.

In one embodiment, R⁵ is (1-4C)alkoxy. In one embodiment, R⁵ is methoxyor ethoxy.

In one embodiment, R⁵ is hydroxy(1-4C)alkyl. In one embodiment, R⁵ ishydroxymethyl or 3-hydroxypropyl.

In one embodiment, R⁵ is (1-4C alkyl)OC(═O)—. In one embodiment, R⁵ isCH₃CH₂OC(═O)—.

In one embodiment, R⁵ is (1-6C)alkylsulfanyl. In one embodiment, R⁵ ismethylsulfanyl (MeS—).

In one embodiment, R⁵ is phenyl optionally substituted with one or moresubstituents independently selected from halogen, (1-6C)alkyl and(1-6C)alkoxy. In one embodiment, R⁵ is phenyl optionally substitutedwith one or more substituents independently selected from F, Cl, methyl,ethyl, methoxy and ethoxy. In one embodiment, R⁵ is phenyl.

In one embodiment, R⁵ is (3-4C)cycloalkyl. In one embodiment, R⁵ iscyclopropyl.

In one embodiment, R⁵ is cyclobutyl.

In one embodiment, R⁵ is amino. In one embodiment, R⁵ is NH₂.

In one embodiment, R⁵ is aminocarbonyl. In one embodiment, R⁵ isH₂NC(═O)—.

In one embodiment, R⁵ is trifluoro(1-3C alkyl)amido. In one embodiment,R⁵ is CF₃C(═O)NH—.

In one embodiment, R⁵ is H, halogen, CN, (1-6C)alkyl, (1-4C)alkoxy,hydroxy(1-4C)alkyl, (1-6C)alkylsulfanyl, or phenyl optionallysubstituted with one or more substituents independently selected fromhalogen, (1-6C)alkyl and (1-6C)alkoxy.

In one embodiment, R⁵ is H, halogen, CN, (1-6C)alkyl, (1-4C)alkoxy,hydroxy(1-4C)alkyl, or phenyl optionally substituted with one or moresubstituents independently selected from halogen, (1-6C)alkyl and(1-6C)alkoxy.

In one embodiment, R⁵ is H, halogen, or (1-6C)alkyl.

In one embodiment, R⁵ is H, methyl, Cl or Br.

In one embodiment, Formula I comprises compounds wherein:

Ring B and the NH—C(═X)—NH moiety are in the trans configuration;R^(a), R^(b), R^(c) and R^(d) are H;

X is O;

R¹ is (1-3C alkoxy)(1-6C)alkyl;

R² is H; Ring B is Ar¹;

Ar¹ is phenyl optionally substituted with one or more substituentsindependently selected from halogen, CF₃, CF₃O—, (1-4C)alkoxy,hydroxy(1-4C)alkyl, (1-6C)alkyl and CN;

Ring C is

R³ is Ar²;Ar² is phenyl optionally substituted with one or more substituentsindependently selected from halogen and (1-6C)alkyl;R⁴ is selected from the structures:

R^(m) is (1-3C)alkyl substituted with 1-3 fluoros, or (3-4C)cycloalkyl;

R^(n) is (1-3C)alkyl;

R^(q) is (1-3C)alkyl optionally substituted with 1-3 fluoros;R^(x) is (1-6C)alkyl, halogen, CN, hydroxy(1-6C)alkyl,trifluoro(1-6C)alkyl, (3-6C)cycloalkyl, (3-6C cycloalkyl)CH₂— (3-6Ccycloalkyl)C(═O)—, (1-3C alkoxy)(1-6C)alkyl, (1-6C)alkoxy,(1-6C)alkylsulfonyl, NH₂, (1-6C alkyl)amino, di(1-6C alkyl)amino,trifluoro(1-3C)alkoxy or trifluoro(1-6C)alkyl;n is 0, 1, 2, 3 or 4;m is 0, 1, 2 or 3;R^(y) is F or (1-3C)alkyl optionally substituted with 1-3 fluoros;p is 0, 1 or 2;R^(z) is (3-4C)cycloalkyl, or (1-3C)alkyl optionally substituted with1-3 fluoros; and

R⁵ is (1-6C)alkyl.

In one embodiment, Formula I comprises compounds wherein:Ring B and the NH—C(═X)—NH moiety are in the trans configuration;R^(a), R^(b), R^(c) and R^(d) are H;

X is O;

R¹ is (1-3C alkoxy)(1-6C)alkyl;

R² is H; Ring B is Ar¹;

Ar¹ is phenyl optionally substituted with one or more halogens;Ring C is formula

R³ is phenyl;R⁴ is selected from the structures:

R^(m) is (1-3C)alkyl substituted with 1-3 fluoros, or (3-4C)cycloalkyl;

R^(n) is (1-3C)alkyl;

R^(q) is (1-3C)alkyl optionally substituted with 1-3 fluoros;R^(x) is (1-6C)alkyl, halogen, CN, hydroxy(1-6C)alkyl,trifluoro(1-6C)alkyl, (3-6C)cycloalkyl, (3-6C cycloalkyl)CH₂— (3-6Ccycloalkyl)C(═O)—, (1-3C alkoxy)(1-6C)alkyl, (1-6C)alkoxy,(1-6C)alkylsulfonyl, NH₂, (1-6C alkyl)amino, di(1-6C alkyl)amino,trifluoro(1-3C)alkoxy or trifluoro(1-6C)alkyl;n is 0, 1, 2, 3 or 4;m is 0, 1, 2 or 3;R^(y) is F or (1-3C)alkyl optionally substituted with 1-3 fluoros;p is 0, 1 or 2;R^(z) is (3-4C)cycloalkyl, or (1-3C)alkyl optionally substituted with1-3 fluoros; and

R⁵ is (1-6C)alkyl.

In another embodiment of Formula I, there is provided compoundsaccording to Formula IA, wherein:

Ring B and the NH—C(═X)—NH moiety are in the trans configuration;R^(a), R^(b), R^(c) and R^(d) are independently selected from H and(1-3C)alkyl,or R^(c) and R^(d) are independently selected from H and (1-3C)alkyl andR^(a) and R^(b) together with the atom to which they are attached form acyclopropyl ring.

X is O, S, NH or N—CN;

R¹ is (1-3C alkoxy)(1-6C)alkyl, (trifluoromethoxy)(1-6C)alkyl, (1-3Csulfanyl)(1-6C)alkyl, monofluoro(1-6C)alkyl, difluoro(1-6C)alkyl,trifluoro(1-6C)alkyl, tetrafluoro(2-6C)alkyl, pentafluro(2-6C)alkyl,cyano(1-6C)alkyl, aminocarbonyl(1-6C)alkyl, hydroxy(1-6C)alkyl,dihydroxy(2-6C)alkyl, (1-6C)alkyl, (1-3 Calkylamino)(1-3C)alkyl, (1-4Calkoxycarbonyl)(1-6C)alkyl, amino(1-6C)alkyl, hydroxy(1-3Calkoxy)(1-6C)alkyl, di(1-3C alkoxy)(1-6C)alkyl, (1-3Calkoxy)trifluoro(1-6C)alkyl, hydroxytrifluoro(1-6C)alkyl, (1-4Calkoxycarbonyl)(1-3C alkoxy)(1-6C)alkyl or hydroxycarbonyl(1-3Calkoxy)(1-6C)alkyl;

R² is H, F, or OH;

Ring B is Ar¹ or hetAr¹;Ar¹ is phenyl optionally substituted with one or more substituentsindependently selected from halogen, CF₃, CF₃O—, (1-4C)alkoxy,hydroxy(1-4C)alkyl, (1-6C)alkyl and CN;hetAr¹ is a 5-6 membered heteroaryl having 1-3 ring heteroatomsindependently selected from N, S and O, and optionally substituted withone or more substituents independently selected from (1-6C)alkyl,halogen, OH, CF₃, NH₂ and hydroxy(1-2C)alkyl;Ring C is formula C-1

R³ is H, (1-6C)alkyl, hydroxy(1-6C)alkyl, Ar², hetCyc¹,(3-7C)cycloalkyl, hetAr², or a C5-C8 bridged carbocyclic ring;Ar² is phenyl optionally substituted with one or more substituentsindependently selected from halogen and (1-6C)alkyl;hetCyc¹ is a 5-6-membered saturated or partially unsaturatedheterocyclic ring having 1-2 ring heteroatoms independently selectedfrom N and O;hetAr² is a 5-6 membered heteroaryl ring having 1-3 ring heteroatomsindependently selected from N, O and S and optionally substituted withone or more substituents independently selected from (1-6C)alkyl andhalogen;R⁴ is selected from the structures:

R^(m) is (1-3C)alkyl substituted with 1-3 fluoros, or (3-4C)cycloalkyl;R^(q) is (1-3C)alkyl optionally substituted with 1-3 fluoros;R^(y) is F or (1-3C)alkyl optionally substituted with 1-3 fluoros;p is 0, 1 or 2;R^(z) is (3-4C)cycloalkyl, or (1-3C)alkyl optionally substituted with1-3 fluoros; and R⁵ is H, (1-6C)alkyl, monofluoro(1-6C)alkyl,difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, tetrafluoro(2-6C)alkyl,pentafluoro(2-6C)alkyl, halogen, CN, (1-4C)alkoxy, hydroxy(1-4C)alkyl,(1-3C alkoxy)(1-4C)alkyl, (1-4C alkyl)OC(═O)—, (1-6C)alkylsulfanyl,phenyl [optionally substituted with one or more substituentsindependently selected from halogen, (1-6C)alkyl and (1-6C)alkoxy],(3-4C)cycloalkyl, amino, aminocarbonyl, or trifluoro(1-3C alkyl)amido.

In one embodiment of Formula IA, R^(a), R^(b), R^(c) and R^(d) are H.

In one embodiment of Formula IA, X is O.

In one embodiment of Formula IA, R¹ is (1-3C alkoxy)(1-6C)alkyl.

In one embodiment of Formula IA, R² is H.

In one embodiment of Formula IA, Ring B is Ar¹, where Ar¹ is phenyloptionally substituted with one or more substituents independentlyselected from halogen, CF₃, CF₃O—, (1-4C)alkoxy, hydroxy(1-4C)alkyl,(1-6C)alkyl and CN.

In one embodiment of Formula IA, R³ is Ar², where Ar² is phenyloptionally substituted with one or more substituents independentlyselected from halogen and (1-6C)alkyl.

In one embodiment of Formula IA, R⁵ is (1-6C)alkyl.

In one embodiment, compounds of Formula IA include compounds wherein:

Ring B and the NH—C(═X)—NH moiety are in the trans configuration;R^(a), R^(b), R^(c) and R^(d) are H;

X is O;

R¹ is (1-3C alkoxy)(1-6C)alkyl;

R² is H; Ring B is Ar¹;

Ar¹ is phenyl optionally substituted with one or more substituentsindependently selected from halogen, CF₃, CF₃O—, (1-4C)alkoxy,hydroxy(1-4C)alkyl, (1-6C)alkyl and CN;

Ring C is

R³ is Ar²;Ar² is phenyl optionally substituted with one or more substituentsindependently selected from halogen and (1-6C)alkyl;R⁴ is selected from the structures:

R^(m) is (1-3C)alkyl substituted with 1-3 fluoros, or (3-4C)cycloalkyl;R^(q) is (1-3C)alkyl optionally substituted with 1-3 fluoros;R^(y) is F or (1-3C)alkyl optionally substituted with 1-3 fluoros;p is 0, 1 or 2;R^(z) is (3-4C)cycloalkyl, or (1-3C)alkyl optionally substituted with1-3 fluoros; and

R⁵ is (1-6C)alkyl.

In one embodiment, compounds of Formula IA include compounds wherein:Ring B and the NH—C(═X)—NH moiety are in the trans configuration;

R^(a), R^(b), R^(c) and R^(d) are H;

X is O;

R¹ is (1-3C alkoxy)(1-6C)alkyl;

R² is H; Ring B is Ar¹;

Ar¹ is phenyl optionally substituted with one or more halogens;

Ring C is

R³ is phenyl;R⁴ is selected from the structures:

and

R⁵ is (1-6C)alkyl.

In another embodiment of Formula I, there is provided compoundsaccording to Formula IB, wherein:

Ring B and the NH—C(═X)—NH moiety are in the trans configuration;R^(a), R^(b), R^(c) and R^(d) are independently selected from H and(1-3C)alkyl,or R^(c) and R^(d) are independently selected from H and (1-3C)alkyl andR^(a) and R^(b) together with the atom to which they are attached form acyclopropyl ring.

X is O, S, NH or N—CN;

R¹ is (1-3C alkoxy)(1-6C)alkyl, (trifluoromethoxy)(1-6C)alkyl, (1-3Csulfanyl)(1-6C)alkyl, monofluoro(1-6C)alkyl, difluoro(1-6C)alkyl,trifluoro(1-6C)alkyl, tetrafluoro(2-6C)alkyl, pentafluro(2-6C)alkyl,cyano(1-6C)alkyl, aminocarbonyl(1-6C)alkyl, hydroxy(1-6C)alkyl,dihydroxy(2-6C)alkyl, (1-6C)alkyl, (1-3 Calkylamino)(1-3C)alkyl, (1-4Calkoxycarbonyl)(1-6C)alkyl, amino(1-6C)alkyl, hydroxy(1-3Calkoxy)(1-6C)alkyl, di(1-3C alkoxy)(1-6C)alkyl, (1-3Calkoxy)trifluoro(1-6C)alkyl, hydroxytrifluoro(1-6C)alkyl, (1-4Calkoxycarbonyl)(1-3C alkoxy)(1-6C)alkyl, or hydroxycarbonyl(1-3Calkoxy)(1-6C)alkyl;

R² is H, F, or OH;

Ring B is Ar¹ or hetAr¹;Ar¹ is phenyl optionally substituted with one or more substituentsindependently selected from halogen, CF₃, CF₃O—, (1-4C)alkoxy,hydroxy(1-4C)alkyl, (1-6C)alkyl and CN;hetAr¹ is a 5-6 membered heteroaryl having 1-3 ring heteroatomsindependently selected from N, S and O, and optionally substituted withone or more substituents independently selected from (1-6C)alkyl,halogen, OH, CF₃, NH₂ and hydroxy(1-2C)alkyl;

Ring C is

R³ is H, (1-6C)alkyl, hydroxy(1-6C)alkyl, Ar², hetCyc¹,(3-7C)cycloalkyl, hetAr², or a C5-C8 bridged carbocyclic ring;Ar² is phenyl optionally substituted with one or more substituentsindependently selected from halogen and (1-6C)alkyl;hetCyc¹ is a 5-6-membered saturated or partially unsaturatedheterocyclic ring having 1-2 ring heteroatoms independently selectedfrom N and O;hetAr² is a 5-6 membered heteroaryl ring having 1-3 ring heteroatomsindependently selected from N, O and S and optionally substituted withone or more substituents independently selected from (1-6C)alkyl andhalogen;R⁴ is selected from the structures:

R^(n) is (1-3C)alkyl;

R^(q) is (1-3C)alkyl optionally substituted with 1-3 fluoros;R^(x) is (1-6C)alkyl, halogen, CN, hydroxy(1-6C)alkyl,trifluoro(1-6C)alkyl, (3-6C)cycloalkyl, (3-6C cycloalkyl)CH₂— (3-6Ccycloalkyl)C(═O)—, (1-3C alkoxy)(1-6C)alkyl, (1-6C)alkoxy,(1-6C)alkylsulfonyl, NH₂, (1-6C alkyl)amino, di(1-6C alkyl)amino,trifluoro(1-3C)alkoxy or trifluoro(1-6C)alkyl;n is 0, 1, 2, 3 or 4;m is 0, 1, 2 or 3;R^(y) is F or (1-3C)alkyl optionally substituted with 1-3 fluoros;p is 0, 1 or 2; andR⁵ is H, (1-6C)alkyl, monofluoro(1-6C)alkyl, difluoro(1-6C)alkyl,trifluoro(1-6C)alkyl, tetrafluoro(2-6C)alkyl, pentafluoro(2-6C)alkyl,halogen, CN, (1-4C)alkoxy, hydroxy(1-4C)alkyl, (1-3C alkoxy)(1-4C)alkyl,(1-4C alkyl)OC(═O)—, (1-6C)alkylsulfanyl, phenyl [optionally substitutedwith one or more substituents independently selected from halogen,(1-6C)alkyl and (1-6C)alkoxy], (3-4C)cycloalkyl, amino, aminocarbonyl,or trifluoro(1-3C alkyl)amido.

In one embodiment of Formula IB, R^(a), R^(b), R^(c) and R^(d) are H.

In one embodiment of Formula IB, X is O.

In one embodiment of Formula IB, R¹ is (1-3C alkoxy)(1-6C)alkyl.

In one embodiment of Formula IB, R² is H.

In one embodiment of Formula IB, Ring B is Ar¹, where Ar¹ is phenyloptionally substituted with one or more substituents independentlyselected from halogen, CF₃, CF₃O—, (1-4C)alkoxy, hydroxy(1-4C)alkyl,(1-6C)alkyl and CN.

In one embodiment of Formula IB, R³ is Ar², where Ar² is phenyloptionally substituted with one or more substituents independentlyselected from halogen and (1-6C)alkyl.

In one embodiment of Formula IB, R⁵ is (1-6C)alkyl.

In one embodiment of Formula IB, R^(x) is selected from halogen,(1-6C)alkyl, (1-6C)alkoxy, CN and cyclopropyl.

In one embodiment of Formula IB, n is 0 or 1.

In one embodiment of Formula IB, n is 0 or 1.

In one embodiment, compounds of Formula IB include compounds wherein:Ring B and the NH—C(═X)—NH moiety are in the trans configuration;

R^(a), R^(b), R^(c) and R^(d) are H;

X is O;

R¹ is (1-3C alkoxy)(1-6C)alkyl;

R² is H; Ring B is Ar¹;

Ar¹ is phenyl optionally substituted with one or more substituentsindependently selected from halogen, CF₃, CF₃O—, (1-4C)alkoxy,hydroxy(1-4C)alkyl, (1-6C)alkyl and CN;

Ring C is

R³ is Ar^(e);Ar² is phenyl optionally substituted with one or more substituentsindependently selected from halogen and (1-6C)alkyl;R⁴ is selected from the structures:

R^(q) is (1-3C)alkyl optionally substituted with 1-3 fluoros;R^(x) is (1-6C)alkyl, halogen, CN, hydroxy(1-6C)alkyl,trifluoro(1-6C)alkyl, (3-6C)cycloalkyl, (3-6C cycloalkyl)CH₂— (3-6Ccycloalkyl)C(═O)—, (1-3C alkoxy)(1-6C)alkyl, (1-6C)alkoxy,(1-6C)alkylsulfonyl, NH₂, (1-6C alkyl)amino, di(1-6C alkyl)amino,trifluoro(1-3C)alkoxy or trifluoro(1-6C)alkyl;n is 0, 1, 2, 3 or 4;m is 0, 1, 2 or 3;R^(y) is F or (1-3C)alkyl optionally substituted with 1-3 fluoros;p is 0, 1 or 2; and

R⁵ is (1-6C)alkyl.

In one embodiment, compounds of Formula IB include compounds wherein:

Ring B and the NH—C(═X)—NH moiety are in the trans configuration;R^(a), R^(b), R^(c) and R^(d) are H;

X is O;

R¹ is (1-3C alkoxy)(1-6C)alkyl;

R² is H; Ring B is Ar¹;

Ar¹ is phenyl optionally substituted with one or more halogens;

Ring C is

R³ is phenyl;R⁴ is selected from the structures:

and

R⁵ is (1-6C)alkyl.

As noted, Ring B and the —NH—C(═X)—NH— moiety of Formulas I, IA and IBare in trans configuration on the pyrrolidine ring, which relativestereochemistry can be illustrated by generic structure A and structureB:

in which the straight thick bars (

) and straight dashed bars (

) indicate relative stereochemistry.

In one embodiment of Formulas I, IA and IB, Ring B and the —NH—C(═X)—NH—moiety are trans in the absolute configuration which can be illustratedby generic structures C and D:

in which the solid wedges (

) and dashed wedges (

) indicate absolute stereochemistry.

It will be appreciated that certain compounds according to the inventionmay contain one or more centers of asymmetry and may therefore beprepared and isolated in a mixture of isomers such as a racemic mixture,or in an enantiomerically pure form.

It will further be appreciated that the compounds of Formula I or theirsalts may be isolated in the form of solvates, and accordingly that anysuch solvate is included within the scope of the present invention. Forexample, compounds of Formula I can exist in unsolvated as well assolvated forms with pharmaceutically acceptable solvents such as water,ethanol, and the like.

The compounds of Formula I include pharmaceutically acceptable saltsthereof. In addition, the compounds of Formula I also include othersalts of such compounds which are not necessarily pharmaceuticallyacceptable salts, and which are useful as intermediates for preparingand/or purifying compounds of Formula I and/or for separatingenantiomers of compounds of Formula I. Particular examples of saltsinclude hydrochloride salts and trifluoroacetate salts.

In one embodiment, the compounds of Formula I include the free base formof compounds of Examples 1-31, or pharmaceutically acceptable saltsthereof.

In one embodiment, the compounds of Formula I include the hydrochloridesalts of compounds of Examples 1-31.

In one embodiment, the compounds of Formula I include thetrifluoroacetate salts of compounds of Examples 1-31.

The term “pharmaceutically acceptable” indicates that the substance orcomposition is compatible chemically and/or toxicologically, with theother ingredients comprising a formulation, and/or the mammal beingtreated therewith.

The present invention also provides a process for the preparation of acompound of Formula I or a salt thereof as defined herein, whichcomprises:

(a) for a compound of Formula I where X is O, coupling a correspondingcompound having the formula II

with a corresponding compound having the formula III

in the presence carbonyldiimidazole or triphosgene and a base; or(b) for a compound of Formula I where X is S, coupling a correspondingcompound having the formula II

with a corresponding compound having the formula III

in the presence di(1H-imidazol-2-yl)methanethione and a base; or(c) for a compound of Formula I where X is O, coupling a correspondingcompound having the formula II

with a corresponding compound having the formula IV

where L¹ is a leaving group, in the presence of a base; or(d) for a compound of Formula I where X is O, coupling a correspondingcompound having the formula V

where L² is a leaving group, with a corresponding compound having theformula III

in the presence of a base; or(e) for a compound of Formula I where X is O, activating a correspondingcompound having the formula VI

with diphenylphosphoryl azide followed by coupling the activatedintermediate with a corresponding compound having the formula III

in the presence a base; or(f) for a compound of Formula I where X is O, coupling a correspondingcompound having the formula II

with a corresponding compound having the formula VII

in the presence of a base; or(g) for a compound of Formula I where X is O, coupling a correspondingcompound having the formula VIII

with a corresponding compound having the formula III

in the presence of a base; or(h) for a compound of Formula I where R¹ is(trifluoromethoxy)(1-6C)alkyl, (1-3C sulfanyl)(1-6C)alkyl,monofluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl,tetrafluoro(2-6C)alkyl, or pentafluoro(2-6C)alkyl, reacting acorresponding compound having the formula IX

with a corresponding compound having the(trifluoromethoxy)(1-6C)alkyl-L³, (1-3C sulfanyl)(1-6C)alkyl-L³,monofluoro(1-6C)alkyl-L³, difluoro(1-6C)alkyl-L³,trifluoro(1-6C)alkyl-L³, tetrafluoro(2-6C)alkyl-L³, orpentafluoro(2-6C)alkyl-L³, where L³ is a leaving atom or a leavinggroup, in the presence of a base; or(i) reacting a compound having the formula X:

where L⁴ is Br or OTf, and R¹, R^(a), R^(b), C^(c), R^(d), R², R³ and R⁵are as defined for Formula I, provided that R⁵ is not halogen, with acorresponding boronic ester or boronic acid having the formula:

respectively, in the presence of a palladium catalyst and a base; andoptionally removing protecting groups and optionally preparing apharmaceutically acceptable salt thereof.

In the above methods, the term “corresponding” means that thedefinitions for the “corresponding compound” are as defined for FormulaI unless stated otherwise.

Referring to method (a), the base may be an amine base, such astriethylamine or diisopropylethylamine. Suitable solvents includedichloromethane, dichloroethane, THF, DMA and DMF. The reaction isconveniently performed at ambient temperature.

Referring to method (b), the base may be an amine base, such astriethylamine or diisopropylethylamine. Suitable solvents includedichloromethane, dichloroethane, THF, DMA and DMF. The reaction isconveniently performed at ambient temperature.

Referring to method (c), the leaving group may be, for example, phenoxyor 4-nitrophenoxy. The base may be an amine base, such as triethylamineor diisopropylethylamine.

Suitable solvents include DMA, DMF and DCE. The reaction is convenientlyperformed at ambient temperature.

Referring to method (d), the leaving group may be, for example, phenoxyor 4-nitrophenoxy. The base may be an amine base, such as triethylamineor diisopropylethylamine. Suitable solvents include DCE, DMA and DMF.The reaction is conveniently performed at ambient temperature.

Referring to method (e), the base may be an amine base, such astriethylamine or diisopropylethylamine. Suitable solvents includetoluene and DMF. The reaction is conveniently performed at elevatedtemperatures, for example the reflux temperature of the solvent.

Referring to method (f), the base may be an amine base, such astriethylamine or diisopropylethylamine. Suitable solvents include DCM,DCE, DMF and THF. The reaction is conveniently performed at temperaturesbetween about 0° C. and ambient temperature.

A compound of Formula VII may be prepared by reacting a compound ofFormula III with bis(trichloromethyl) carbonate in the presence of abase, such as an amine base.

Referring to method (h), the base may be an amine base, such astriethylamine or diisopropylethylamine. Suitable solvents include DMF,DMA and THF. The reaction is conveniently performed at temperaturesbetween ambient temperature and 60° C.

Referring to method (i), the reaction is conveniently performed in thepresence of a ligand, such as PPh₃ or tricyclohexylphosphine. Suitablepalladium catalysts include Pd₂dba₃ or Pd(PPh₃)₄. Suitable bases includean alkali metal carbonate, such as sodium carbonate, potassiumcarbonate, cesium carbonate, or potassium phosphate. Examples ofsuitable solvents include dioxane, toluene, or DME. The reaction isconveniently performed at temperatures between 80-110° C.

Amine groups in compounds described in any of the above methods may beprotected with any convenient amine protecting group, for example asdescribed in Greene & Wuts, eds., “Protecting Groups in OrganicSynthesis”, 2^(nd) ed. New York; John Wiley & Sons, Inc., 1991. Examplesof amine protecting groups include acyl and alkoxycarbonyl groups, suchas t-butoxycarbonyl (BOC) and [2-(trimethylsilyl)ethoxy]methyl (SEM).Likewise, carboxyl groups may be protected with any convenient carboxylprotecting group, for example as described in Greene & Wuts, eds.,“Protecting Groups in Organic Synthesis”, 2^(nd) ed. New York; JohnWiley & Sons, Inc., 1991. Examples of carboxyl protecting groups include(1-6C)alkyl groups, such as methyl, ethyl and t-butyl. Alcohol groupsmay be protected with any convenient alcohol protecting group, forexample as described in Greene & Wuts, eds., “Protecting Groups inOrganic Synthesis”, 2^(nd) ed. New York; John Wiley & Sons, Inc., 1991.Examples of alcohol protecting groups include benzyl, trityl, silylethers, and the like.

The compounds of the formulas II, III, III, IV, V, VI, VII and VIII areprovided as further aspects of the invention. In one embodiment, Thecompounds of the formulas II, III, III, IV, V, VI, VII and VIII areuseful as intermediates for the synthesis of compounds of Formula I.

In one embodiment of the above-described processes (a), (b), (c), and(f), where ring B is Ar¹ and R^(a), R^(b), R^(d) and R² are hydrogen, asingle enantiomer of intermediate II, namely enantiomer 1 of II-A isprepared by chiral crystallization prior to use. Accordingly, in oneembodiment, a process for preparing enantiomer 1 of II-A comprises:

preparing racemic trans II-A

where Ring B and the NH₂ group are in the trans configuration; Ring B isAr¹ or hetAr¹; Ar¹ is phenyl optionally substituted with one or moresubstituents independently selected from halogen, CF₃, CF₃O—,(1-4C)alkoxy, hydroxy(1-4C)alkyl, (1-6C)alkyl and CN; and hetAr¹ is a5-6 membered heteroaryl having 1-3 ring heteroatoms independentlyselected from N, S and O, and optionally substituted with 1-2 groupsindependently selected from (1-6C)alkyl, halogen, OH, CF₃, NH₂ andhydroxy(1-2C)alkyl; said method comprising:treating racemic trans II-A with di-p-toluoyl-D-tartaric acid to providethe di-p-toluoyl-D-tartaric acid salt of racemic trans II-A;recrystallizing the di-p-toluoyl-D-tartaric acid salt of trans II-A toprovide the di-p-toluoyl-D-tartaric acid salt of enantiomer 1 of transII-A; andtreating the di-p-toluoyl-D-tartaric acid salt of enantiomer 1 of transII-A with an inorganic base to provide free base of enantiomer 1 oftrans II-A having the absolute configuration as illustrated:

In one embodiment of enantiomer 1 of trans II-A, R¹ is 2-methoxyethoxyand Ring B is 4-fluorophenyl, and racemic trans II-A is prepared by theprocess comprising: reacting 4-fluorobenzaldehyde with nitromethane inthe presence of acetic acid and ammonium acetate to provide(E)-1-fluoro-4-(2-nitrovinyl)benzene

reacting (E)-1-fluoro-4-(2-nitrovinyl)benzene with2-methoxy-N-(methoxymethyl)-N-((trimethylsilyl)methyl)ethanamine in thepresence of a catalytic amount of an acid (such as TFA) to providetrans-3-(4-fluorophenyl)-1-(2-methoxyethyl)-4-nitropyrrolidine

andtreating trans-3-(4-fluorophenyl)-1-(2-methoxyethyl)-4-nitropyrrolidinewith platinum (IV) oxide or Raney Nickel in a hydrogen atmosphere toprovide trans-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine

wherein the 4-fluorophenyl and amino group are in the transconfiguration.

In one embodiment of enantiomer 1 of trans II-A, R¹ is 2-methoxyethoxyand Ring B is 3,4-difluorophenyl.

In one embodiment, the inorganic base is an alkali metal hydroxide suchas sodium hydroxide.

A similar process as above may be used utilizing di-p-toluoyl-L-tartaricacid to provide enantiomer 2 of II-A:

where R¹ and Ring B are as defined herein. In one embodiment ofenantiomer 2 of trans II-A, R¹ is 2-methoxyethoxy and Ring B is4-fluorophenyl. In one embodiment of enantiomer 2 of trans II-A, R¹ is2-methoxyethoxy and Ring B is 3,4-difluorophenyl.The ability of compounds of the invention to act as TrkA inhibitors maybe demonstrated by the assay described in Example A.

Compounds of Formula I are useful in the treatment of pain, cancer,inflammation/inflammatory diseases, neurodegenerative diseases, certaininfectious diseases, Sjogren's syndrome, endometriosis, diabeticperipheral neuropathy, prostatitis or pelvic pain syndrome.

In one embodiment, compounds of Formula I are useful for treating pain,including chronic and acute pain. For example, compounds of Formula Iare useful in the treatment of multiple types of pain includinginflammatory pain, neuropathic pain, and pain associated with cancer,surgery or bone fracture.

In one embodiment, compounds of Formula I are useful for treating acutepain. Acute pain, as defined by the International Association for theStudy of Pain, results from disease, inflammation, or injury to tissues.This type of pain generally comes on suddenly, for example, after traumaor surgery, and may be accompanied by anxiety or stress, and is confinedto a given period of time and severity. In some instances, it can becomechronic.

In one embodiment, compounds of Formula I are useful for treatingchronic pain. Chronic pain, as defined by the International Associationfor the Study of Pain, is widely believed to represent a disease initself. It can be made much worse by environmental and psychologicalfactors. Chronic pain persists over a longer period than acute pain andis resistant to most medical treatments, generally over 3 months ormore. It can and often does cause severe problems for patients.

Compounds of Formula I are also useful for treating cancer. Particularexamples include neuroblastoma, ovarian, pancreatic, colorectal andprostate cancer.

Compounds of Formula I are also useful for treating inflammation andcertain infectious diseases. For example, compounds of Formula I may beused to treat interstitial cystitis (IC), painful bladder syndrome(PBS), urinary incontinence, asthma, atopic dermatitis, and psoriasis.

Compounds of Formula I are also useful for treating a neurodegenerativedisease in a mammal, comprising administering to said mammal one or morecompounds of Formula I or a pharmaceutically acceptable salt thereof inan amount effective to treat said neurodegenerative disease. In oneembodiment, compounds of Formula I may also be used to treatdemyelination and dysmyelination by promoting myelination, neuronalsurvival, and oligodendrocyte differentiation via blocking Sp35-TrkAinteraction. In one embodiment, the neurodegenerative disease ismultiple sclerosis. In one embodiment, the neurodegenerative disease isParkinson's disease. In one embodiment, the neurodegenerative disease isAlzheimer's disease.

Compounds of Formula I are also useful for treating certain infectiousdiseases such as Trypanosoma cruzi infection in a mammal.

Compounds of Formula I are also useful for treating Sjogren's syndromein a mammal.Compounds of Formula I are also useful for treating endometriosis in amammal.Compounds of Formula I are also useful for treating diabetic peripheralneuropathy in a mammal.Compounds of Formula I are also useful for treating prostatitis in amammal.Compounds of Formula I are also useful for treating pelvic pain syndromein a mammal.Compounds of Formula I are also useful in treating diseases related toan imbalance of the regulation of bone remodeling, such as osteoporosis,rheumatoid arthritis, and bone metastases.

As used herein, terms “treat” or “treatment” refer to therapeutic orpalliative measures. Beneficial or desired clinical results include, butare not limited to, alleviation, in whole or in part, of symptomsassociated with a disorder or condition, diminishment of extent ofdisease, stabilized (i.e., not worsening) state of disease, delay orslowing of disease progression, amelioration or palliation of thedisease state, and remission (whether partial or total), whetherdetectable or undetectable. “Treatment” can also mean prolongingsurvival as compared to expected survival if not receiving treatment.

In certain embodiments, compounds of Formula I are useful for preventingdiseases and disorders as defined herein. The term “preventing” as usedherein means the prevention of the onset, recurrence or spread, in wholeor in part, of the disease or condition as described herein, or asymptom thereof, and includes to the administration of a compound ofFormula I prior to the onset of symptoms.

Accordingly, one embodiment of this invention provides a method oftreating pain in a mammal, comprising administering to said mammal inneed thereof one or more compounds of Formula I or a pharmaceuticallyacceptable salt thereof in an amount effective to treat said pain. Inone embodiment, the pain is chronic pain. In one embodiment, the pain isacute pain. In one embodiment, the pain is inflammatory pain,neuropathic pain, or pain associated with cancer, surgery, or bonefracture.

Another embodiment of this invention provides a method of preventingpain in a mammal, comprising administering to said mammal in needthereof one or more compounds of Formula I or a pharmaceuticallyacceptable salt thereof in an amount effective to prevent said pain. Inone embodiment, the pain is chronic pain. In one embodiment, the pain isacute pain. In one embodiment, the pain is inflammatory pain,neuropathic pain, or pain associated with cancer, surgery, or bonefracture.

Another embodiment of this invention provides a method of treatingcancer in a mammal, comprising administering to said mammal in needthereof one or more compounds of Formula I or a pharmaceuticallyacceptable salt thereof in an amount effective to treat said cancer. Inone embodiment, provided herein is a method for treating a patientdiagnosed with a cancer having a dysregulation of TrkA, comprisingadministering to the patient a therapeutically effective amount of acompound of the invention or a pharmaceutically acceptable salt thereof.

In one embodiment, the dysregulation of TrkA comprises overexpression ofwild-type TrkA (autocrine activation).

In one embodiment, the dysregulation of TrkA comprises one or morechromosome translocations or inversions resulting in TrkA gene fusions.In one embodiment, the dysregulation is a result of genetictranslocations in which the expressed protein is a fusion proteincontaining residues from non-TrkA and TrkA proteins, and at a minimumthe TrkA kinase domain. In one embodiment, the TrkA fusion protein isLMNA-TrkA, TFG-TrkA, TPM3-TrkA, CD74-TrkA, NFASC-TrkA, MPRIP-TrkA,BCAN-TrkA, or TPR-TrkA, where:

LMNA=Prelamin-A/C;

TFG=TRK-fused gene protein;

TPM3=Tropomysin alpha-3;

CD74=HLA class II histocompatibility antigen gamma chain;

NFASC=Neurofascin;

MPRIP=MPRIP protein;

BCAN=Brevican core protein; and

TPR=Nucleoprotein TPR

In one embodiment, the dysregulation of TrkA comprises one or moredeletions, insertions or mutations in the TrkA protein. In oneembodiment, the dysregulation comprises a deletion of one or moreresidues from the TrkA protein, resulting in constitutive activity ofTrkA kinase. In one embodiment the deletion includes deletion ofresidues 303-377 in TrkA Isoform 2.

In one embodiment, the dysregulation of TrkA comprises a splicevariation in which the expressed protein is an alternatively splicedvariant of TrkA having one or more residues deleted resulting inconstitutive activity of TrkA kinase. In one embodiment, analternatively spliced form of TrkA with constitutive activity hasdeletions of exons 8, 9, and 11 resulting in an expressed proteinmissing residues 192-284 and 393-398 relative to TrkA Isoform 2.

Cancers identified as having dysregulation of TrkA (see literaturereferences below; also see www.cancer.gov and www nccn.org) include:(A) Cancers wherein the dysregulation of TrkA comprises one or morechromosome translocations or inversions resulting in TrkA gene fusions,including:

Cancer Literature reference(s) Standard of Care Non-Small Cell Vaishnaviet al. 2013: radiotherapy (e.g. radioiodide therapy, Lung Cancer NatureMedicine 19, external-beam radiation, radium 223 1469-1472 therapy),chemotherapeutics as single agents (e.g. afatinib dimaleate,bevacizumab, carboplatin, cetuximab, cisplatin, crizotinib, erlotinib,gefitinib, gemcitabine, methotrexate, paclitaxel, pemetrexed) orcombinations (e.g. carboplatin-paclitaxel, gemcitabine- paclitaxel,chemoradiation) Papillary Thyroid Caria et al. 2010: CancerRadiotherapies (e.g. radioiodide therapy, Carcinoma Genetics andexternal-beam radiation) and Cytogenetics 203: 21-29 chemotherapeutics(e.g. sorafenib, sunitinib, pazopanib) Glioblastoma Frattini et al.2013: Chemotherapeutics (e.g. bevacizumab, Multiforme Nature Genet.everolimus, lomustine, temozolomide) 45(10): 1141-9 ColorectalMartin-Zanca et al. Chemotherapeutics as single agents Carcinoma 1986:Nature 319: 743 (aflibercept, bevacizumab, capecitabine, cetuximab,fluorouracil, irinotecan, leucovorin, oxaliplatin, panitumumab,regorafenib) or combinations (e.g. folfox, folfiri, capox,folfiri-bevacizumab, folfiri- cetuximab, xelox) Melanoma WO 2013/059740A1 Chemotherapeutics (e.g. aldesleukin, dabrafenib, dacarbazine,interferon alfa- 2b, ipilimumab, peginterferon alfa-2b, trametinib,vemurafenib)(B) Cancers wherein the dysregulation of TrkA comprises one or moredeletions, insertions or mutations in the TrkA protein, including:

Cancer Literature reference(s) Standard of care Acute Myeloid Meyer2007: Leukemia 21: Chemotherapeutics as single leukemia 2171-2180 agents(e.g. arsenic trioxide, Reuther et al. 2000: Mol Cell cyclophosphamide,cytarabine, Biol 20: 8655-8666 daunorubicin, doxorubicin, vincristine)or combinations (e.g. ADE) Large Cell Marchetti et al 2008: HumanRadiotherapy (e.g. radioiodide Neuroendocrine Mutation 29(5): 609-616therapy, external-beam radiation, Carcinoma radium 223 therapy) and/orchemotherapeutics (e.g. cisplatin, carboplatin, etoposide) NeuroblastomaTacconelli et al 2004: Cancer Chemotherapeutics (e.g. Cell 6: 347cyclophosphamide, doxorubicin, vincristine)(C) Cancers driven by overexpression of wild-type TrkA (autocrineactivation), including:

Cancer Literature Reference(s) Standard of care Prostate Carcinoma Walchet al: Clinical & Radiotherapy (e.g. radium 223 Experimental Metastasis17: therapy) or chemotherapeutics 307-314 (e.g. abiraterone,cabazitaxel, Papatsoris et al 2007: Expert degarelix, denosumab,docetaxel, Opinion on Investigational Drugs enzalutamide, leuprolide,16(3): 303-309 prednisone, sipuleucel-T) Neuroblastoma Van Noesel et al2004: Gene Chemotherapeutics (e.g. 325: 1-15 cyclophosphamide,doxorubicin, vincristine) Pancreatic Zhang et al 2005: OncologyChemotherapeutics as single Carcinoma Reports 14: 161-171 agents (e.g.erlotinib, fluorouracil, gemcitabine, mitomycin C) or combinations (e.g.gemcitabine-oxaliplatin) Melanoma Truzzi et al 2008: Journal ofChemotherapeutics (e.g. Investigative Dermatology aldesleukin,dabrafenib, 128(8): 2031 dacarbazine, interferon alfa-2b, ipilimumab,peginterferon alfa- 2b, trametinib, vemurafenib) Head and NeckKolokythas et al 2010: Journal of Radiotherapy and/or Squamous Cell Oraland Maxillofacial Surgery chemotherapeutics (e.g. Carcinoma 68(6):1290-1295 bleomycin, cetuximab, cisplatin, docetaxel, fluorouracil,methotrexate) Gastric Carcinoma Ni et al 2012: Asian PacificChemotherapeutics (e.g. Journal of Cancer Prevention docetaxel,doxorubucin, 13: 1511 fluorouracil, mitomycin C, trastuzumab)

In one embodiment, provided herein is a method for treating a patientdiagnosed with a cancer having a dysregulation of TrkA, comprisingadministering to the patient a therapeutically effective amount of acompound of the invention, or a pharmaceutically acceptable saltthereof, wherein the cancer is selected from non-small cell lung cancer,papillary thyroid carcinoma, glioblastoma multiforme, acute myeloidleukemia, colorectal carcinoma, large cell neuroendocrine carcinoma,prostate cancer, neuroblastoma, pancreatic carcinoma, melanoma, head andneck squamous cell carcinoma and gastric carcinoma.

In one embodiment, the compounds of the present invention are useful fortreating cancer in combination with one or more additional therapeuticagents or therapies that work by the same or a different mechanism ofaction.

In one embodiment, the additional therapeutic agent(s) is selected fromreceptor tyrosine kinase-targeted therapeutic agents, includingcabozantinib, crizotinib, erlotinib, gefitinib, imatinib, lapatinib,nilotinib, pazopanib, pertuzumab, regorafenib, sunitinib, andtrastuzumab.

In one embodiment, the additional therapeutic agent(s) is selected fromsignal transduction pathway inhibitors, including Ras-Raf-MEK-ERKpathway inhibitors (e.g. sorafenib, trametinib, vemurafenib),PI3K-Akt-mTOR-S6K pathway inhibitors (e.g. everolimus, rapamycin,perifosine, temsirolimus) and modulators of the apoptosis pathway (e.g.obataclax).

In one embodiment, the additional therapeutic agent(s) is selected fromcytotoxic chemotherapeutics, including arsenic trioxide, bleomycin,cabazitaxel, capecitabine, carboplatin, cisplatin, cyclophosphamide,cytarabine, dacarbazine, daunorubicin, docetaxel, doxorubicin,etoposide, fluorouracil, gemcitabine, irinotecan, lomustine,methotrexate, mitomycin C, oxaliplatin, paclitaxel, pemetrexed,temozolomide, and vincristine.

In one embodiment, the additional therapeutic agent(s) is selected fromangiogenesis-targeted therapies, including aflibercept and bevacizumab.

In one embodiment, the additional therapeutic agent(s) is selected fromimmune-targeted agents, including aldesleukin, ipilimumab,lambrolizumab, nivolumab, sipuleucel-T.

In one embodiment, the additional therapeutic agent(s) is selected fromagents active against the TrkA pathway, including NGF-targetedbiopharmaceuticals such as NGF antibodies, and panTrk inhibitors.

In one embodiment, the additional therapeutic agent or therapy isradiotherapy, including radioiodide therapy, external-beam radiation andradium 223 therapy.

In one embodiment, the additional therapeutic agent(s) includes any oneof the above listed therapies or therapeutic agents which are standardsof care in cancers wherein the cancer has a dysregulation of TrkA.

In one embodiment, provided herein is a method of treating cancer in apatient, comprising administering to said patient a compound of theinvention or a pharmaceutically acceptable salt thereof, in combinationwith at least one additional therapy or therapeutic agent selected fromradiotherapy (e.g. radioiodide therapy, external-beam radiation, radium223 therapy), cytotoxic chemotherapeutics (e.g. arsenic trioxide,bleomycin, cabazitaxel, capecitabine, carboplatin, cisplatin,cyclophosphamide, cytarabine, dacarbazine, daunorubicin, docetaxel,doxorubicin, etoposide, fluorouracil, gemcitabine, irinotecan,lomustine, methotrexate, mitomycin C, oxaliplatin, paclitaxel,pemetrexed, temozolomide, vincristine), tyrosine kinasetargeted-therapeutics (e.g. afatinib, cabozantinib, cetuximab,crizotinib, dabrafenib, erlotinib, gefitinib, imatinib, lapatinib,nilotinib, pazopanib, panitumumab, pertuzumab, regorafenib, sunitinib,trastuzumab), apoptosis modulators and signal transduction inhibitors(e.g. everolimus, perifosine, rapamycin, sorafenib, temsirolimus,trametinib, vemurafenib), immune-targeted therapies (e.g. aldesleukin,interferon alfa-2b, ipilimumab, lambrolizumab, nivolumab, prednisone,sipuleucel-T) and angiogenesis-targeted therapies (e.g. aflibercept,bevacizumab), wherein the amount of the compound of the invention or apharmaceutically acceptable salt thereof is, in combination with theadditional therapy or therapeutic agent, is effective in treating saidcancer. These additional therapeutic agents may be administered with oneor more compounds of the invention as part of the same or separatedosage forms, via the same or different routes of administration, and onthe same or different administration schedules according to standardpharmaceutical practice known to one skilled in the art.

Also provided herein is (i) a pharmaceutical combination for treatingcancer in a patient in need thereof, which comprises (a) a compound ofthe invention or a pharmaceutically acceptable salt thereof, (b) anadditional therapeutic agent and (c) optionally at least onepharmaceutically acceptable carrier for simultaneous, separate orsequential use for the treatment of a tumor disease, wherein the amountsof the compound or salt thereof and of the additional therapeutic agentare together effective in treating said cancer; (ii) a pharmaceuticalcomposition comprising such a combination; (iii) the use of such acombination for the preparation of a medicament for the treatment ofcancer; and (iv) a commercial package or product comprising such acombination as a combined preparation for simultaneous, separate orsequential use; and to a method of treatment of cancer a patient in needthereof.

In one embodiment, the combination therapy is for treating a cancer isselected from non-small cell lung cancer, papillary thyroid carcinoma,glioblastoma multiforme, acute myeloid leukemia, colorectal carcinoma,large cell neuroendocrine carcinoma, prostate cancer, neuroblastoma,pancreatic carcinoma, melanoma, head and neck squamous cell carcinomaand gastric carcinoma.

Another embodiment of this invention provides a method of treatinginflammation or an inflammatory disease or disorder in a mammal,comprising administering to said mammal in need thereof one or morecompounds of Formula I or a pharmaceutically acceptable salt thereof inan amount effective to treat said inflammation. In one embodiment, theinflammatory disease is inflammatory lung diseases (such as asthma),interstitial cystitis, bladder pain syndrome, inflammatory boweldiseases (including ulcerative colitis and Crohn's disease), andinflammatory skin diseases such as atopic dermatitis.

In one embodiment, the method of treating inflammation or aninflammatory disease or disorder comprises administering a compound ofthe invention in combination with one or more additional agents.Examples of additional agents include anti-TNF treatments (for examplemonoclonal antibody such as infliximab (Remicade), adalimumab (Humira),certolizumab pegol (Cimzia), and golimumab (Simponi), or a circulatingreceptor fusion protein such as etanercept (Enbrel)), antimetabolite andantifolate drug (for example Methotrexate), or targeted kinaseinhibitors (for example JAK family inhibitors Ruxolitinib, Tofacitinib,CYT387, Lestaurtinib, Pacritinib and TG101348).

Another embodiment of this invention provides a method of treatingTrypanosoma cruzi infection in a mammal, comprising administering tosaid mammal in need thereof one or more compounds of Formula I or apharmaceutically acceptable salt thereof in an amount effective to treatsaid Trypanosoma cruzi infection.

Another embodiment of this invention provides a method of treatingSjogren's syndrome in a mammal, comprising administering to said mammalin need thereof one or more compounds of Formula I or a pharmaceuticallyacceptable salt thereof in an amount effective to treat said syndrome.

Another embodiment of this invention provides a method of treatingendometriosis in a mammal, comprising administering to said mammal inneed thereof one or more compounds of Formula I or a pharmaceuticallyacceptable salt thereof in an amount effective to treat saidendometriosis.

Another embodiment of this invention provides a method of treatingdiabetic peripheral neuropathy in a mammal, comprising administering tosaid mammal in need thereof one or more compounds of Formula I or apharmaceutically acceptable salt thereof in an amount effective to treatsaid diabetic peripheral neuropathy.

Another embodiment of this invention provides a method of treatingprostatitis in a mammal, comprising administering to said mammal in needthereof one or more compounds of Formula I or a pharmaceuticallyacceptable salt thereof in an amount effective to treat saidprostatitis.

Another embodiment of this invention provides a method of treatingpelvic pain syndrome in a mammal, comprising administering to saidmammal in need thereof one or more compounds of Formula I or apharmaceutically acceptable salt thereof in an amount effective to treatsaid pelvic pain syndrome.

Another embodiment of this invention provides a method of treating aneurodegenerative disease in a mammal, comprising administering to saidmammal in need thereof one or more compounds of Formula I or apharmaceutically acceptable salt thereof in an amount effective to treatsaid neurodegenerative disease.

Another embodiment of this invention provides a method of treatingdiseases related to an imbalance of the regulation of bone remodeling ina mammal, comprising administering to said mammal in need thereof one ormore compounds of Formula I or a pharmaceutically acceptable saltthereof in an amount effective to treat said disease. In one embodiment,the disease is osteoporosis, rheumatoid arthritis, and bone metastases.

In one embodiment, the method for treating diseases related to animbalance of the regulation of bone remodeling in a mammal comprisesadministering a TrkA inhibitor of the invention in combination with oneor more additional therapeutic agents or therapies. Examples ofadditional therapeutic agents or therapies include anti-TNF treatments(for example monoclonal antibody such as infliximab (Remicade),adalimumab (Humira), certolizumab pegol (Cimzia), and golimumab(Simponi), or with a circulating receptor fusion protein such asetanercept (Enbrel)), antimetabolite and antifolate drug (for exampleMethotrexate), or targeted kinase inhibitors (for example JAK familyinhibitors Ruxolitinib, Tofacitinib, CYT387, Lestaurtinib, Pacritiniband TG101348).

As used herein, an “effective amount” means an amount of compound that,when administered to a mammal in need of such treatment, is sufficientto (i) treat a particular disease, condition, or disorder which can betreated with a compound of Formula I, or (ii) attenuate, ameliorate, oreliminate one or more symptoms of the particular disease, condition, ordisorder described herein.

The amount of a compound of Formula I that will correspond to such anamount will vary depending upon factors such as the particular compound,disease condition and its severity, the identity (e.g., weight) of themammal in need of treatment, but can nevertheless be routinelydetermined by one skilled in the art.

As used herein, the term “mammal” refers to a warm-blooded animal thathas or is at risk of developing a disease described herein and includes,but is not limited to, guinea pigs, dogs, cats, rats, mice, hamsters,and primates, including humans.

The compounds of the present invention can be used in combination withone or more additional therapeutic agents that work by the same or adifferent mechanism of action. Examples of additional therapeutic agentsinclude anti-inflammatory compounds, steroids (e.g., dexamethasone,cortisone and fluticasone), analgesics such as NSAIDs (e.g., aspirin,ibuprofen, indomethacin, and ketoprofen), and opioids (such asmorphine), and chemotherapeutic agents.

Also provided herein is a pharmaceutical combination comprising aneffective amount of: (a) at least one compound of Formula I; and (b) atleast one additional therapeutic agent selected from anti-inflammatorycompounds, steroids (e.g., dexamethasone, cortisone and fluticasone),analgesics such as NSAIDs (e.g., aspirin, ibuprofen, indomethacin, andketoprofen), and opioids (such as morphine), for use in the treatment ofpain in a mammal, wherein (a) and (b) can be in separate dosage forms orin the same dosage form.

The term “pharmaceutical combination” as used herein refers to apharmaceutical therapy resulting from the mixing or combining of morethan one active ingredient and includes both fixed and non-fixedcombinations of the active ingredients. The term “fixed combination”means that at least one of the compounds of Formula I, and at least oneadditional therapeutic agent are both administered to a patientsimultaneously in the form of a single entity or dosage. The term“non-fixed combination” means that at least one of the compounds ofFormula I, and at least one additional therapeutic agent, areadministered to a patient as separate entities either simultaneously orsequentially with variable intervening time limits, wherein suchadministration provides effective levels of the two or more compounds inthe body of the patient. These also apply to cocktail therapies, e.g.the administration of three or more active ingredients.

Also provided herein is a method of treating pain in a mammal,comprising co-administering to a mammal in need thereof an effectiveamount of: (a) at least one compound of

Formula I; and (b) at least one additional therapeutic agent selectedfrom anti-inflammatory compounds, steroids (e.g., dexamethasone,cortisone and fluticasone), analgesics such as NSAIDs (e.g., aspirin,ibuprofen, indomethacin, and ketoprofen), opioids (such as morphine),calcitonin gene-related peptide receptor antagonists, subtype-selectiveion channel modulators, anticonvulsants (for example Pregabalin andgabapentin), dual serotonin-norepinephrin reuptake inhibitors (forexample duloxetine, venlafaxine and milnacipran), and tricyclicantidepressants (such as amitriptyline, nortriptyline and desipramine).

The term “co-administering” is meant to encompass administration of theselected therapeutic agents to a single patient, and is intended toinclude treatment regimens in which the agents are administered by thesame or different route of administration or at the same or differenttimes. This term encompasses administration of two or more agents to amammal so that both agents and/or their metabolites are present in themammal at the same time. It includes simultaneous administration inseparate compositions, administration at different times in separatecompositions, and/or administration in a composition in which bothagents are present. In some embodiments, the compound(s) of theinvention and the other therapeutic agent(s) are administered in asingle composition. In some embodiments, compound(s) of the inventionand the other agent(s) are admixed in the composition.

Also provided herein is a medicament containing a compound of Formula Ifor treatment of pain in a mammal in combination with an additionaltherapeutic agent selected from anti-inflammatory compounds, steroids(e.g., dexamethasone, cortisone and fluticasone), analgesics such asNSAIDs (e.g., aspirin, ibuprofen, indomethacin, and ketoprofen), andopioids (such as morphine).

Also provided herein is a medicament containing a therapeutic agentselected from anti-inflammatory compounds, steroids (e.g.,dexamethasone, cortisone and fluticasone), analgesics such as NSAIDs(e.g., aspirin, ibuprofen, indomethacin, and ketoprofen), and opioids(such as morphine) for treatment of pain in a mammal in combination witha compound of Formula I. Compounds of the invention may be administeredby any convenient route, e.g. into the gastrointestinal tract (e.g.rectally or orally), the nose, lungs, musculature or vasculature, ortransdermally or dermally. Compounds may be administered in anyconvenient administrative form, e.g. tablets, powders, capsules,solutions, dispersions, suspensions, syrups, sprays, suppositories,gels, emulsions, patches etc. Such compositions may contain componentsconventional in pharmaceutical preparations, e.g. diluents, carriers, pHmodifiers, sweeteners, bulking agents, and further active agents. Ifparenteral administration is desired, the compositions will be sterileand in a solution or suspension form suitable for injection or infusion.Such compositions form a further aspect of the invention.

Another formulation may be prepared by mixing a compound describedherein and a carrier or excipient. Suitable carriers and excipients arewell known to those skilled in the art and are described in detail in,e.g., Ansel, Howard C., et al., Ansel's Pharmaceutical Dosage Forms andDrug Delivery Systems. Philadelphia: Lippincott, Williams & Wilkins,2004; Gennaro, Alfonso R., et al. Remington: The Science and Practice ofPharmacy. Philadelphia: Lippincott, Williams & Wilkins, 2000; and Rowe,Raymond C. Handbook of Pharmaceutical Excipients. Chicago,Pharmaceutical Press, 2005. The formulations may also include one ormore buffers, stabilizing agents, surfactants, wetting agents,lubricating agents, emulsifiers, suspending agents, preservatives,antioxidants, opaquing agents, glidants, processing aids, colorants,sweeteners, perfuming agents, flavoring agents, diluents and other knownadditives to provide an elegant presentation of the drug (i.e., acompound described herein or pharmaceutical composition thereof) or aidin the manufacturing of the pharmaceutical product (i.e., medicament).

Accordingly, another aspect of the present invention provides apharmaceutical composition, which comprises a compound of Formula I or apharmaceutically acceptable salt thereof, as defined hereinabove,together with a pharmaceutically acceptable diluent or carrier.According to another embodiment, the present invention provides acompound of Formula I or a pharmaceutically acceptable salt thereof, foruse in the treatment of pain in a mammal. In one embodiment, the pain ischronic pain. In one embodiment the pain is acute pain. In oneembodiment, the pain is inflammatory pain, neuropathic pain, or painassociated with cancer, surgery, or bone fracture.

According to another embodiment, the present invention provides acompound of Formula I or a pharmaceutically acceptable salt thereof, foruse in the treatment of cancer in a mammal.

In another embodiment, the present invention provides a compound ofFormula I or a pharmaceutically acceptable salt thereof, for use in thetreatment of inflammation or an inflammatory disease or disorder in amammal. In one embodiment, the inflammatory disease is inflammatory lungdiseases (such as asthma), interstitial cystitis, bladder pain syndrome,inflammatory bowel diseases (including ulcerative colitis and Crohn'sdisease), and inflammatory skin diseases such as atopic dermatitis.

In another embodiment, the present invention provides a compound ofFormula I or a pharmaceutically acceptable salt thereof, for use in thetreatment of infectious diseases, for example Trypanosoma cruziinfection, in a mammal.

In another embodiment, the present invention provides a compound ofFormula I or a pharmaceutically acceptable salt thereof, for use in thetreatment of Sjogren's syndrome in a mammal.

In another embodiment, the present invention provides a compound ofFormula I or a pharmaceutically acceptable salt thereof, for use in thetreatment of endometriosis in a mammal.

In another embodiment, the present invention provides a compound ofFormula I or a pharmaceutically acceptable salt thereof, for use in thetreatment of diabetic peripheral neuropathy in a mammal,

In another embodiment, the present invention provides a compound ofFormula I or a pharmaceutically acceptable salt thereof, for use in thetreatment of prostatitis in a mammal, In another embodiment, the presentinvention provides a compound of Formula I or a pharmaceuticallyacceptable salt thereof, for use in the treatment of pelvic painsyndrome in a mammal,

In another embodiment, the present invention provides a compound ofFormula I or a pharmaceutically acceptable salt thereof, for use in thetreatment of a neurodegenerative disease in a mammal.

According to a further aspect, the present invention provides the use ofa compound of Formula I or a pharmaceutically acceptable salt thereof,in the manufacture of a medicament for the treatment of a conditionselected from pain, cancer, inflammation, neurodegenerative disease orTrypanosoma cruzi infection. In one embodiment, the condition is chronicpain. In one embodiment, the condition is acute pain. In one embodiment,the pain is inflammatory pain, neuropathic pain, or pain associated withcancer, surgery, or bone fracture. In one embodiment, the condition iscancer. In one embodiment, the condition is inflammation. In oneembodiment, the condition is a neurodegenerative disease. In oneembodiment, the condition is Trypanosoma cruzi infection. In oneembodiment, the condition is Sjogren's syndrome. In one embodiment, thecondition is endometriosis. In one embodiment, the condition is diabeticperipheral neuropathy. In one embodiment, the condition is prostatitis.In one embodiment, the condition is pelvic pain syndrome.

EXAMPLES

The following examples illustrate the invention. In the examplesdescribed below, unless otherwise indicated all temperatures are setforth in degrees Celsius. Reagents were purchased from commercialsuppliers such as Aldrich Chemical Company, Lancaster, TCI or Maybridge,and were used without further purification unless otherwise indicated.

The reactions set forth below were done generally under a positivepressure of nitrogen or argon or with a drying tube (unless otherwisestated) in anhydrous solvents, and the reaction flasks were typicallyfitted with rubber septa for the introduction of substrates and reagentsvia syringe. Glassware was oven dried and/or heat dried.

Column chromatography was done on a Biotage system (Manufacturer: DyaxCorporation) having a silica gel or C-18 reverse phase column, or on asilica SepPak cartridge (Waters).

Biological Assay Example A TrkA Kinase Binding Assay

TrkA binding activity was determined in a TrkA LanthaScreen™ Eu KinaseBinding Assay. 5 nM His-tagged recombinant human TrkA (6HIS taggedcytoplasmic domain from Invitrogen, Catalog No. PV3144) was incubatedwith 4 nM Alexa-Fluor® Tracer 236 (Invitrogen Cat. No. PV5592), 2 nMbiotinylated anti-His (Invitrogen Cat. No. PV6090), and 2 nMeuropium-labeled Streptavidin (Invitrogen Cat. No. PV5899), in buffer(25 mM MOPS, pH 7.5, 5 mM MgCl₂, 0.005% Triton X-100). Three fold serialdilutions of compounds of the invention in DMSO were added to a finalpercentage of 2% DMSO. After 60-minute incubation at 22° C., thereaction was measured using the EnVision mutlimode plate reader(PerkinElmer) via TR-FRET dual wavelength detection at 615 nM and 665nM. The percent of control was calculated using a ratiometric emissionfactor. The IC₅₀ values were determined by fitting a four parametermodel to the percent of control data.

Table A provides averaged IC₅₀ values for compounds of the inventionwhen tested in the assay of Example A, where A represents an averagedIC₅₀ value <100 nM.

Example B p38 Kinase Binding Assay

p38α binding activity was determined in a p38a LanthaScreen™ Eu KinaseBinding Assay. 5 nM of inactive, GST-tagged recombinant human p38a(GST-tagged cytoplasmic domain from Invitrogen, Catalog No. PV3305) wasincubated with 5 nM Alexa-Fluor® Tracer 199 (Invitrogen Cat. No.PV5830), and 2 nM europium labeled anti-GST antibody (Invitrogen Cat.No. PV5594), in buffer (25 mM [Na²] HEPES pH 7.3, 10 mM MgCl₂, 100 μMNaVO₄). Three fold serial dilutions of compounds of the invention inDMSO were added to a final percentage of 2% DMSO. After 60-minuteincubation at 22° C., the reaction was measured using the EnVisionmultimode plate reader (PerkinElmer) via TR-FRET dual wavelengthdetection at 615 nM and 665 nM. The percent of control was calculatedusing a ratiometric emission factor. The IC₅₀ values were determined byfitting a four parameter model to the percent of control data. Thecompounds of Examples 1-31 were tested in this assay, and all compoundswere found to be 1000 fold more potent against TrkA than p38α.

TABLE A Example TrkA Enzyme No. IC₅₀ (nM) 1 A 2 A 3 A 4 A 5 A 6 A 7 A 8A 9 A 10 A 11 A 12 A 13 A 14 A 15 A 16 A 17 A 18 A 19 A 20 A 21 A 22 A23 A 24 A 25 A 26 A 27 A 28 A 29 A 30 A 31 A

Example C Off-Target Kinase Profiling

Two representative compounds (Example 2, 14) of the invention weretested for off-target kinase activity at a concentration of 10 μM byMillipore, Inc. in their KinaseProfiler™ service against all the kinasesavailable in their full kinase panel. These compounds were run induplicate at a concentration of ATP near the Km for each individualkinase according to Millipore's specifications. The results are shown inTable B. Data are reported as percent of control (POC) and are theaverage of the two replicates.

In the KinaseProfiler™ the compounds of Example 2 and Example 14 showedremarkable and unexpected selectivity for inhibiting TrkA versus otherkinases in the panel. In fact, the compounds were largely inactiveagainst off-target kinases at a concentration of 10 and thus would notbe expected to inhibit off-target kinases at therapeutic doses inmammals. The ability of compounds of the invention to selectivelyinhibit the Trk pathway without inhibiting other off-target kinasescould translate into drug profiles that are essentially free ofside-effects related to inhibition of off-target kinases. Such a drugprofile would represent a safer approach to treating pain, inflammation,cancer and certain skin diseases than has been previously reported.

TABLE B Example 2 Example 14 Kinase Avg POC Avg POC Abl2 101 95.5 Abl-P113.5 102.5 AKT1 109.5 98.5 AKT2 113 119.5 AKT3 110 104 ALK 111 102.5ALK4 112.5 115 AMPK(A1/B1/G1) 118 106.5 ARK5 89 85 AURKA 116 106 Axl 117103 BLK 92 91.5 Bmx 115.5 105.5 BrSK1 104 94 BrSK2 93 99 BTK 109 97.5CAMK1 107 103.5 CAMK1d 100 103.5 CAMK2b 90.5 93 CAMK2d 91.5 105.5 CAMK2g89.5 99 CAMK4 97.5 83.5 CDK1/cyclinB 104 97 CDK2/cyclinA 111 113.5CDK2/cyclinE 103 98.5 CDK3/cyclinE 98 100.5 CDK5/p25 104 99 CDK5/p35 113115.5 CDK6/cyclinD3 96 99.5 CDK7/cyclinH/MAT1 88 97.5 CDK9/cyclinT1 104104 CHK1 114.5 104.5 CHK2 101 97.5 CK1_y 103 97.5 CK1delta 108 108.5CK1gamma1 92 80 CK1gamma2 73.5 53 CK1gamma3 87.5 95 CK2alpha2 119.5 120CLK2 125 111.5 CLK3 94 94 c-RAF 103.5 89 CSK 113 103 DAPK1 97 99.5 DAPK2109 107 DAPK3 107 105.5 DCAMKL2 105 114.5 DDR2 100.5 96 DMPK 98.5 105DRAK1 86.5 101.5 DYRK2 90.5 85 eEF-2K 98.5 103 EGFR 105.5 96.5 EphA1 9799 EphA2 110.5 96 EphA3 101.5 106.5 EphA4 108.5 103.5 EphA5 102.5 101.5EphA7 101.5 106.5 EphA8 104.5 104.5 EphB1 93.5 97.5 EphB2 109.5 120EphB3 105.5 138.5 EphB4 104 96 ErbB4 98 101.5 ERK1 103 78.5 ERK2 106.592.5 FAK 111.5 98.5 FAK2 99.5 107 Fer 105 100.5 Fes 135.5 125 FGFR1106.5 101.5 FGFR2 91.5 103 FGFR3 111.5 133.5 FGFR4 105.5 110 Fgr 108.580.5 Flt1 86 81 Flt3 119.5 90 Flt4 95 92.5 Fms 101.5 76 Fyn 97 91.5 GRK5103.5 91 GRK6 96.5 97 GRK7 104 97 GSK3alpha 94 101.5 GSK3beta 108 114.5Haspin 71.5 96 Hck 116.5 108.5 HIPK1 96.5 97.5 HIPK2 95 99 HIPK3 99.5 89IGF-1R 63 79 IGF-1R Activated 102 106 IKKalpha 121 118.5 IKKbeta 87 99IR 74.5 84 IR Activated 106.5 100.5 IRAK1 112.5 108.5 IRAK4 132 110.5IRR 105 96 ITK 111 101 JAK2 112.5 109 JAK3 103.5 101 JNK1alpha1 98 105JNK2alpha2 100 97 JNK3 111.5 121 KDR 116.5 99 KIT 101.5 101.5 Lck 113112.5 LIMK1 100 98 LKB1 89.5 103.5 LOK 109 105 Lyn 112 105.5 MAP3K5 97.5104 MAP4K2 105.5 99.5 MAPKAP-K2 111 101 MAPKAP-K3 101.5 105.5 MAPKAP-K5100 123.5 MARK1 97.5 98 MARK2 90 99.5 MEK1 100.5 91 MELK 110 111.5 Mer90.5 78 Met 106 96.5 MINK 98 89.5 MKK4_m 115 116.5 MKK6 106.5 99.5 MKK797.5 111 MKNK2 101 101 MLK1 103.5 102 MRCKalpha 113 124.5 MRCKbeta 10598.5 MSK1 102.5 106 MSK2 120 116 MSSK1 118 109 MST1 94 97.5 MST2 99.5101 MST3 101 105.5 mTOR 108.5 102.5 mTOR/FKBP12 108.5 113 MuSK 103.598.5 MYLK 86.5 101.5 NEK11 97 91 NEK2 96 97.5 NEK3 97 101 NEK6 105.5 102NEK7 117 106.5 NLK 111.5 108.5 p38alpha 112 101 p38beta 101.5 93p38delta 107.5 102.5 p38gamma 92 92.5 p70S6K 105.5 98 PAK2 95.5 92.5PAK4 103.5 100.5 PAK5 103 107 PAK6 106 102 PASK 102.5 100.5 PDGFRalpha110.5 114.5 PDGFRbeta 108.5 120 PDK1 94.5 101.5 PhKgamma2 90 88 Pim-199.5 103.5 Pim-2 86.5 103.5 Pim-3 104 108.5 PKAC-alpha 94.5 109 PKCalpha96 93 PKCbetaI 95 101 PKCbetaII 101.5 92 PKCdelta 102.5 99.5 PKCepsilon103.5 114.5 PKCeta 108.5 100 PKCgamma 100.5 89.5 PKCiota 95 104.5PKCtheta 98.5 98 PKCzeta 100 99.5 PKD1 96 97 PKD2 101.5 108 Plk1 100 113Plk2 99.5 102 Plk3 101 93.5 PRK2 105 106.5 PRKG1alpha 108 100.5PRKG1beta 97.5 101.5 PrKX 110.5 94 PTK5 108 91 PTK6 101 108.5 Ret 106.584 RIPK2 105.5 93.5 ROCK-I 98 109.5 ROCK-II 102.5 93.5 Ron 122.5 104 Ros105 91 Rse 96 96.5 Rsk1 111 111.5 Rsk2 106 99.5 Rsk3 98 96 Rsk4 136.5113.5 SGK1 98.5 99 SGK2 99 100 SGK3 106 107 SIK 106.5 96 SRC 105 103.5SRPK1 97.5 109.5 SRPK2 96.5 102.5 STK33 94 103.5 Syk 86 88 TAK1 93 88TAO1 102.5 96.5 TAO2 97 102.5 TAO3 97.5 100.5 TBK1 116.5 103 TECActivated 107 83.5 Tie2 71.5 71 TLK2 92.5 93.5 TNK2 109.5 97.5 TrkA 0.51 TrkB 1.5 4.5 TSSK1 105 104.5 TSSK2 107 107.5 Txk 99.5 98.5 ULK2 96.5106.5 ULK3 100 98 VRK2 101.5 109.5 WNK2 98 99.5 WNK3 99 96 Yes 104 55.5ZAP-70 93 101

Preparation of Synthetic Intermediates Preparation A

2-methoxy-N-(methoxymethyl)-N-((trimethylsilyl)methyl)ethanamine Step A:Preparation of 2-methoxy-N-((trimethylsilyl)methyl)ethanamine

To a DMSO solution (15 mL) of 2-methoxyethanamine (14.2 mL, 163 mmol) at90° C. was added a DMSO (10 mL) solution of(chloromethyl)trimethylsilane (11.4 mL, 81.5 mmol) by addition funnelover 40 minutes. The mixture was heated at 90° C. for 3.5 hours thencooled to ambient temperature. The mixture was then diluted with H₂O(150 mL) and extracted with EtOAc (2×150 mL). The combined organicextracts were washed with brine (150 mL), dried with MgSO₄, filtered andconcentrated to yield the product as a yellow oil (8.14 g, 62% yield).MS (apci) m/z=162.0 (M+H).

Step B: Preparation of2-methoxy-N-(methoxymethyl)-N-((trimethylsilyl)methyl)ethanamine

A MeOH (2.45 mL) solution of formaldehyde (37% aqueous, 4.91 g, 60.6mmol) was cooled to 0° C., and treated with a dropwise addition of2-methoxy-N-((trimethylsilyl)methyl)ethanamine (8.14 g, 50.5 mmol). Thebiphasic mixture was stirred at 0° C. for 3 hours, then K₂CO₃ (6.97 g,50.5 mmol) was added and the mixture was stirred at 0° C. for 1 hour.The yellow oil was decanted onto K₂CO₃ (2.00 g, 14.4 mmol), and themixture was stirred at ambient temperature for 2 hours. After the yellowoil was decanted, the solid K₂CO₃ was washed with Et₂O (2×10 mL), andthe Et₂O washings were combined with the decanted yellow oil andconcentrated on a rotary evaporator to yield the title compound as ayellow oil (9.92 g, 96% yield). ¹H NMR (CDCl₃) δ 4.00 (s, 2H), 3.37-3.43(m, 2H), 3.29 (s, 3H), 3.19 (s, 3H), 2.77-2.82 (m, 2H), 2.18 (s, 2H),0.00 (s, 9H).

Preparation B1

(3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine Step A:Preparation of (E)-1-fluoro-4-(2-nitrovinyl)benzene

Acetic acid (2.0 L, 35.5 mol) and ammonium acetate (310.5 g, 4.03 mol)were stirred at ambient temperature for 1 hour, then nitromethane (611mL, 11.3 mol) and 4-fluorobenzaldehyde (200 g, 1.61 mol) were added andthe reaction mixture was heated to 90° C. for 3 hours. The reaction wasallowed to cool to ambient temperature, then H₂O (4 L) was added over 2hours with mechanical stirring. The suspension was stirred 1 hour, thenfiltered and washed with 2:1 water/acetic acid (500 mL). The solids weredried in a vacuum oven (50° C.) to afford the title product as a paleyellow solid (238 g, 1.42 mol, 88% yield). ¹H NMR (CDCl₃) δ 7.98 (1H),7.55 (3H), 7.16 (2H).

Step B: Preparation oftrans-3-(4-fluorophenyl)-1-(2-methoxyethyl)-4-nitro-pyrrolidine

To a suspension of (E)-1-fluoro-4-(2-nitrovinyl)benzene (201 g, 1.20mol) in DCM (1.09 L) and TFA (9.3 mL, 120 mmol) was added dropwise over30 minutes2-methoxy-N-(methoxymethyl)-N-((trimethylsilyl)methyl)ethanamine(Preparation A; 383 g, 1.86 mol) and the internal reaction temperaturewas maintained between 23-36° C. by cooling in an ice bath. The reactionmixture was poured into aqueous phosphate buffer solution (pH 7, 500 mL)and diluted with DCM (300 mL). The phases were separated and the aqueousphase was extracted with DCM (400 mL). The organic phases were combined,washed with brine (300 mL), dried (MgSO₄), filtered and concentratedunder reduced pressure. The crude oil was purified by silica columnchromatography eluting with 40% EtOAc/heptane to afford the titlecompound as a yellow oil (245 g, 76% yield). MS (apci) m/z=269.1 (M+H).

Step C: Preparation oftrans-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine

To a solution oftrans-3-(4-fluorophenyl)-1-(2-methoxyethyl)-4-nitropyrrolidine (289 g,1.08 mol) in EtOH (1 L) was added platinum(IV) oxide (24.5 g, 108 mmol)in a Parr vessel and installed into a Parr shaker. The vessel wasevacuated and backfilled with nitrogen (3×), then evacuated andbackfilled with hydrogen (60 psi). The vessel was recharged withhydrogen as needed until the reaction was complete. The reaction mixturewas filtered through Celite® and rinsed with MeOH (50 mL), thenconcentrated under reduced pressure to afford the title compound as ayellow oil (243 g, 95% yield). MS (apci) m/z=239.1 (M+H).

Step D: Preparation of(3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine(2S,3S)-2,3-bis(4-methylbenzoyloxy)succinate

To a solution of(3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine (120 g,504 mmol) in THF (3.0 L) and H₂O (333 mL) was addeddi-p-toluoyl-D-tartaric acid (195 g, 504 mmol). Stirred at ambienttemperature for 1 hour, then placed in a freezer (−11° C.) for 18 hours.The mixture was stirred to give a slurry, filtered, and rinsed with Et₂O(4×100 mL). The solid was dried in vacuum oven (40° C.) for 4 hours,then recrystallized twice by the following procedure: the solid wasdissolved in THF (1.06 mL) and H₂O (118 mL) with heating to 45° C., thenallowing to cool to ambient temperature over 2 hours, then placed in afreezer (−11° C.) for 18 hours; the mixture was stirred to give aslurry, filtered, and rinsed with Et₂O (4×100 mL). After tworecrystallizations, the solid was dried in vacuum oven (40° C.) for 18hours to afford the title compound as a white crystalline solid (96 g,31% yield). MS (apci) m/z=239.2 (M+H).

Step E: Preparation of(3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine

(3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine(2S,3S)-2,3-bis(4-methylbenzoyloxy)succinate (20 g, 32.0 mmol) wasdissolved in DCM (300 mL) and washed with 1M NaOH (2×200 mL). Thecombined aqueous phases were extracted with DCM (200 mL). The combinedorganic extracts were washed with brine (200 mL), dried (MgSO₄),filtered and concentrated, then dried under vacuum to afford the titlecompound as a yellow oil (6.17 g, 81%, >99% ee). MS (apci) m/z=239.1(M+H).

The following pyrrolidine intermediates B2 and B3 were made according tothe method of Preparation B1, Steps A-E, including chiralcrystallization and using the appropriate benzaldehyde in Step A andreplacing EtOH and platinum (IV) oxide with MeOH and Raney nickelrespectively in Step C. Intermediates B4-B7 were made according to themethod of Preparation B1, Steps A-C.

Preparation # Structure Name Data B2

(3S,4R)-4-(3,5- difluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3- amineMS (apci) m/z = 257.1 (M + H) B3

(3S,4R)-4-(3,4- difluorophenyl)-1-(2- methoxyethyl)pyrrolidin-3- amine(2S,3S)-2,3-bis(4- methylbenzoyloxy)succinate MS (apci) m/z = 257.1 (M +H) B4

trans-4-(3-chloro-4-fluoro- phenyl)-1-(2- methoxyethyl)pyrrolidin-3-amine MS (apci) m/z = 273.1 (M + H) B5

trans-4-(4-chloro-3-fluoro- phenyl)-1-(2- methoxyethyl)pyrrolidin-3-amine MS (apci) m/z = 273.1 (M + H) B6

trans-4-(3-chloro-5-fluoro- phenyl)-1-(2- methoxyethyl)pyrrolidin-3-amine MS (apci) m/z = 273.1 (M + H) B7

trans-4-(3-chlorophenyl)-1- (2-methoxyethyl)pyrrolidin- 3-amine MS(apci) m/z = 255.1 (M + H)

Preparation C

(3S,4R)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-aminedihydro chloride Step A: Preparation of(E)-3-(3,4,5-trifluorophenyl)acryloyl chloride

To a suspension of (E)-3-(3,4,5-trifluorophenyl)acrylic acid (5.15 g,25.5 mmol) in toluene (50 mL) was added oxalyl chloride (4.43 mL, 51.0mmol) and the mixture was stirred for 5 minutes at ambient temperature.The mixture was cooled to 0° C. and DMF (0.0493 mL, 0.637 mmol) wasadded (immediate, mild gas evolution). The mixture was stirred for 10minutes, the ice bath was removed and the mixture allowed to reachambient temperature (sustained gas evolution). Stirring was continuedfor 16 hours and the mixture was concentrated in vacuo. The residue wasdissolved in Et₂O (100 mL), treated with activated carbon and filteredthrough a packed Celite® plug capped with a MgSO₄ layer (Et₂O elution).The filtrate was concentrated in vacuo to afford(E)-3-(3,4,5-trifluorophenyl)acryloyl chloride (6.1 g, 109%) as a faintgreen oil which was used directly in the next step. ¹H NMR (CDCl₃) δ7.66 (d, J=15.6 Hz, 1H), 7.22 (m, 2H), 6.57 (d, J=15.6 Hz, 1H) ppm.

Step B: Preparation of(R,E)-4-phenyl-3-(3-(3,4,5-trifluorophenyl)acryloyl)oxazolidin-2-one

A solution of (R)-4-phenyloxazolidin-2-one (3.92 g, 24.0 mmol) in THF(60 mL) was cooled to −78° C. and lithium bis(trimethylsilyl)amide (25.2mL, 25.2 mmol, 1.0 M in THF) was added dropwise over 10 minutes. Themixture was stirred at −78° C. for 45 minutes and a solution of(E)-3-(3,4,5-trifluorophenyl)acryloyl chloride (5.56 g, 25.2 mmol) inTHF (15 mL) was added. The mixture was stirred for 17 hours during whichtime the mixture reached ambient temperature and was poured into coldwater (300 mL). The aqueous mixture was extracted with 50% EtOAc/hexanes(3×) and the combined organic phases were washed with brine, dried overMgSO₄/activated carbon and filtered through a packed SiO₂ plug cappedwith a MgSO₄ layer (50% EtOAc/hexanes for elution). The filtrate wasconcentrated in vacuo to afford(R,E)-4-phenyl-3-(3-(3,4,5-trifluorophenyl)acryloyl)oxazolidin-2-one(8.40 g, 100%) as an ivory white solid. ¹H NMR (CDCl₃) δ 7.84 (d, J=15.7Hz, 1H), 7.57 (d, J=15.7 Hz, 1H), 7.42-7.33 (m, 5H), 7.21-7.18 (m, 2H),5.54 (dd, J=8.7, 3.9 Hz, 1H), 4.75 (t, J=8.8 Hz, 1H), 4.34 (dd, J=8.9,3.9 Hz, 1H) ppm.

Step C: Preparation of(R)-3-((3S,4R)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidine-3-carbonyl)-4-phenyloxazolidin-2-one

A solution of(R,E)-4-phenyl-3-(3-(3,4,5-trifluorophenyl)acryloyl)oxazolidin-2-one(9.50 g, 27.4 mmol) and TFA (2.11 mL, 2.74 mmol) in toluene (270 mL) wascooled to 0° C. and2-methoxy-N-(methoxymethyl)-N-((trimethylsilyl)methyl)ethanamine(Preparation A, 8.43 g, 41.0 mmol) in toluene (25 mL) was added dropwiseover 15 minutes. The mixture was stirred for 2.5 hours at 0° C., wastreated with 1M K₂CO₃ (200 mL) and warmed to ambient temperature. Theorganic layer was separated and was washed with water and brine. Thesolution was dried over MgSO₄ and filtered through a packed SiO₂ plugcapped with a MgSO₄ layer eluting with Et₂O then 30% EtOAc/hexanes. Thefiltrate was concentrated and the residue purified by silica columnchromatography eluting with 25% EtOAc/hexanes to afford(R)-3-((3S,4R)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidine-3-carbonyl)-4-phenyloxazolidin-2-one(7.1 g, 58% yield) as a colorless syrup. ¹H NMR (CDCl₃) δ 7.42-7.35 (m,3H), 7.28-7.26 (m, 2H), 6.96-6.93 (m, 2H), 5.40 (dd, J=8.8, 4.1 Hz, 1H),4.67 (t, J=8.9 Hz, 1H), 4.26 (dd, J=9.0, 4.1 Hz, 1H), 4.12 (q, J=14.3,7.1 Hz, 1H), 4.14-4.01 (m, 1H), 3.47 (t, J=5.7 Hz, 2H), 3.39 (t, J=9.5Hz, 1H), 3.33 (s, 3H), 3.02 (m, 1H), 2.73-2.59 (m, 4H) ppm.

Step D: Preparation of(3S,4R)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidine-3-carboxylicacid

A 1M aqueous solution of LiOH (39.0 mL, 39.0 mmol) was cooled to 0° C.and H₂O₂ (3.37 mL, 33.0 mmol, 30 wt %) was added. The chilled mixturewas added to solution of(R)-3-((3S,4R)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidine-3-carbonyl)-4-phenyloxazolidin-2-one(7.0 g, 15.6 mmol) in THF (75 mL) over 30 minutes at 0° C. Afterstirring for 1 hour, 2.0 M aqueous Na₂SO₃ (33.0 mL, 65.9 mmol) wasintroduced and the reaction mixture was warmed to ambient temperature.After stirring for 2 hours, the mixture was diluted with water (100 mL)and acidified with 6 N HCl to pH 5. The mixture was treated with NaCland extracted with 10% iPrOH/DCM (8×). The combined organic layers weredried over Na₂SO₄ and filtered through a packed Celite® plug capped witha MgSO₄ layer eluting with DCM. The filtrate was concentrated in vacuoto afford(3S,4R)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidine-3-carboxylicacid (4.0 g, 85% yield) as a colorless syrup. MS (apci) m/z=304.1 (M+H).

Step E: Preparation of benzyl(3S,4R)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-ylcarbamate

To a solution of(3S,4R)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidine-3-carboxylicacid (4.0 g, 11.9 mmol) in toluene (50 mL) was added DIEA (5.18 mL, 29.7mmol) followed by diphenyl phosphoryl azide (5.3 mL, 27.3 mmol). Themixture was stirred at ambient temperature for 1 hour and then heated toreflux for 1 hour. Benzyl alcohol (2.47 mL, 23.7 mmol) was added and thereaction mixture was refluxed for 3 hours. The reaction mixture wascooled to ambient temperature and added to water (150 mL). The layerswere separated and the aqueous layer was extracted with EtOAc (2×). Thecombined organic phases were washed with brine, dried overMgSO₄/activated carbon and filtered through packed Celite®. The filtratewas concentrated in vacuo and the residue purified by silica columnchromatography (50% EtOAc/hexanes, EtOAc, 5% MeOH/EtOAc step gradient)to afford benzyl(3S,4R)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-ylcarbamate(1.07 g, 22% yield) as a bronze syrup. MS (apci) m/z=409.1 (M+H).

Step F: Preparation of(3S,4R)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-aminedihydrochloride

A mixture of benzyl(3S,4R)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-ylcarbamate(1.05 g, 2.31 mmol) and TFA (15 mL) was heated at 60° C. for 7 hours.Additional TFA (10 mL) was added and the mixture heated at 75° C. for 1hour. The reaction mixture was cooled to ambient temperature andconcentrated in vacuo. The residue was dissolved in a minimal amount ofDCM and added dropwise to 1M HCl in Et₂O (200 mL) at 0° C. The resultingsuspension was filtered and the collected solid was washed with etherand dried in vacuo to afford the title compound (785 mg, 98% yield) as alight grey powder. ¹H NMR (D₂O) δ 7.06-7.10 (m, 2H), 4.13-4.20 (m, 1H),3.92-3.99 (m, 2H), 3.71-3.74 (m, 1H), 3.57-3.63 (m, 3H), 3.41-3.49 (m,3H), 3.25 (s, 3H) ppm.

Preparation D

(3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-aminedihydrochloride Step A: Preparation of tert-butyl(3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-ylcarbamate

A solution of tert-butyl(3S,4R)-4-(3-fluorophenyl)pyrrolidin-3-ylcarbamate (250 mg, 0.89 mmol,commercially available), DIEA (0.48 mL, 2.68 mmol) and1-bromo-2-methoxyethane (149 mg, 1.07 mmol) in DMF (3 mL) was stirred atambient temperature for 2 hours, then heated to 60° C. for 4 hours, thencooled to ambient temperature overnight. After partitioning betweenEtOAc and saturated NaHCO₃ (10 mL each), the organic layer was washedwith water and brine (2×10 mL each), dried over Na₂SO₄, filtered andconcentrated to yield tert-butyl(3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-ylcarbamate(250 mg, 83% yield) as a viscous orange oil. LCMS (apci) m/z=339.1(M+H).

Step B: Preparation of(3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-aminedihydrochloride

A solution of tert-butyl(3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-ylcarbamate(250 mg, 0.74 mmol) in 5-6 N HCl in isopropyl alcohol (14.8 mL, 73.9mmol) was stirred at ambient temperature for 1 hour. The mixture wasconcentrated in vacuo and triturated with Et₂O to afford the titlecompound (230 mg, 100% yield) as beige solid. LCMS (apci) m/z=239.1(M+H).

Preparation A-100

tert-butyl trans-4-phenylpyrrolidin-3-ylcarbamate Step A: Preparation oftrans-1-benzyl-3-nitro-4-phenylpyrrolidine

To a DCM (2 L) solution of (E)-(2-nitrovinyl)benzene (149 g, 1.00 mol)was added TFA (19.5 mL, 0.250 mol), followed by cooling to 15° C. andthen slow addition of a DCM (500 mL) solution ofN-methoxymethyl-N-(trimethylsilylmethyl)benzylamine (274 g, 1.00 mol)over 3 hours, maintaining the reaction temperature between 15 and 10° C.The reaction was warmed up to ambient temperature and stirred for 18hours, then washed with 2 N NaOH (500 mL) and treated with 2 N HCl (1L). The resulting white suspension was stirred for 1 hour before beingfiltered and washed with DCM. DCM (1 L) and 2 N NaOH (750 mL) were thenadded to the collected white solid and stirred until all soliddissolved. After phase-separation, the aqueous layer was extracted withDCM (2×1 L). The combined organic layers were dried with MgSO₄, filteredand concentrated to afford the title product as an off-white solid (205g, 73% yield). MS (apci) m/z=283.1 (M+H).

Step B: Preparation of trans-1-benzyl-4-phenylpyrrolidin-3-amine

To a suspension of trans-1-benzyl-3-nitro-4-phenyl-pyrrolidine (93.9 g,333 mmol) in EtOH (1.20 L) was added concentrated HCl (450 mL), followedby addition of zinc dust (173 g, 2.66 mol) in small portions over 1.5hours while maintaining the temperature between 55-60° C. The reactionmixture was stirred at ambient temperature for 18 hours, then cooled inan ice/water bath followed by addition of concentrated NH₄OH (900 mL).The mixture (pH=10-11) was filtered and the collected zinc was washedwith CHCl₃. The filtrate was then phase-separated, and the aqueous layerwas extracted with CHCl₃ (2×400 mL). The combined organics was washedwith H₂O, brine, dried with MgSO₄, filtered and concentrated to affordthe title compound as an amber oil (85.0 g, 100% yield). MS (apci)m/z=253.2 (M+H).

Step C: Preparation oftrans-(1-benzyl-4-phenyl-pyrrolidin-3-yl)-carbamic acid tert-butyl ester

To a mixture of trans-1-benzyl-4-phenylpyrrolidin-3-amine (85.0 g, 333mmol), THF (750 mL) and triethylamine (69.6 mL, 500 mmol), was slowlyadded (Boc)₂O (72.7 g, 333 mmol) in portions over 30 minutes. Thereaction mixture was stirred at ambient temperature for 16 hours and wasconcentrated in vacuo. The residue was dissolved in CHCl₃ and was washedwith aqueous Na₂CO₃ and brine. The organic layer was dried with MgSO₄,filtered and concentrated to afford the title compound as a pale-yellowsolid (116 g, 99% yield). MS (apci) m/z=353.0 (M+H).

Step D: Preparation of tert-butyl trans-4-phenylpyrrolidin-3-ylcarbamate

A 2 gallon Parr reactor was charged withtrans-(1-benzyl-4-phenyl-pyrrolidin-3-yl)-carbamic acid tert-butyl ester(114 g, 323 mmol), EtOH (2 L) and 10% Pd/C (50% wet, 11.0 g). Thereactor was purged with N₂ several times, filled with H₂ to 56-57 psiand agitated at 80° C. When the reaction was complete according to HPLCanalysis, the reaction mixture was filtered and the filtrateconcentrated to provide the crude product as a yellow solid. The crudematerial was triturated from toluene to afford the title product as awhite solid (68.4 g, 78% yield). MS (apci) m/z=262.9 (M+H).

Preparation A-101

trans-tert-butyl 3-amino-4-phenylpyrrolidine-1-carboxylate Step A:Preparation oftrans-N-(1-benzyl-4-phenylpyrrolidin-3-yl)-2,2,2-trifluoroacetamide

To a solution of trans-1-benzyl-4-phenylpyrrolidin-3-amine (PreparationA-100, Step B, 61.9 g, 245 mmol) in DCM (400 mL) was added DIEA (64.1mL, 368 mmol) and the mixture was cooled in an ice bath. Trifluoroaceticanhydride (38.1 mL, 270 mmol) was added dropwise over 30 minutes under aN₂ atmosphere. After the addition, the mixture was stirred for 30minutes and then concentrated in vacuo. The residue was dissolved in DCMand washed with saturated aqueous NaHCO₃ and brine. The solution wasdried with MgSO₄, filtered and concentrated in vacuo. The crude materialwas treated with hexanes and the resulting yellow suspension was stirredat ambient temperature for 1 hour. The solid was collected byfiltration, washed with hexanes and dried under vacuum to afford thetitle compound (78.7 g, 92% yield) as a yellow solid. MS (apci)m/z=349.1 (M+H).

Step B: Preparation oftrans-tert-butyl-3-phenyl-4-(2,2,2-trifluoroacetamido)pyrrolidine-1-carboxylate

A solution of trans-N-(1-benzyl-4-phenylpyrrolidin-3-yl)-2,2,2-trifluoroacetamide (78.7 g, 226 mmol) in EtOH(400 mL) was purged with N₂ and treated with 20% Pd(OH)₂ on activatedcarbon (31.7 g, 45.2 mmol). The mixture was agitated at ambienttemperature under 30 psi of H₂ in a parr reactor for 7 hours, and thenfiltered through GF/F paper and concentrated in vacuo. The residue wasdissolved in DCM (250 mL), followed by the addition of TEA (49.4 mL, 355mmol) and cooling in an ice bath. Boc₂O (56.8 g, 260 mmol) was addedslowly over 15 minutes and the reaction mixture was warmed to ambienttemperature and stirred for 1 hour. The mixture was washed withsaturated aqueous NaHCO₃ and brine, then dried with MgSO₄. The solutionwas filtered, concentrated and the residue was purified by silica columnchromatography eluting with 40% EtOAc/hexanes to provide the titlecompound as a white solid (63.2 g, 75% yield). ¹H NMR (CDCl₃) δ7.23-7.39 (m, 5H), 6.36 (br s, 1H), 4.47-4.55 (m, 1H), 3.92-4.00 (m,1H), 3.78-4.00 (m, 1H), 3.50-3.59 (m, 1H), 3.22-3.45 (m, 2H), 1.49 (s,9H).

Step C: Preparation of trans-tert-butyl3-amino-4-phenylpyrrolidine-1-carboxylate

A solution of trans tert-butyl3-phenyl-4-(2,2,2-trifluoroacetamido)pyrrolidine-1-carboxylate (63.2 g,176 mmol) in MeOH (200 mL) was cooled in an ice bath and 2 N NaOH (220mL, 440 mmol) was added. The reaction mixture was allowed to warm toambient temperature overnight, then concentrated to approximately 200 mLand diluted with H₂O (200 mL). The aqueous mixture was extracted withDCM and the combined extracts were washed with brine and dried overNa₂SO₄. The solution was filtered and concentrated to give the titlecompound as a light yellow oil (46.2 g, 99% yield). MS (apci) m/z=163.0(M+H-Boc).

Preparation B-100

trans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-amine dihydrochloride StepA: Preparation of tert-butyltrans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-ylcarbamate

To a solution of tert-butyl trans-4-phenylpyrrolidin-3-ylcarbamate(Preparation A-100, 4.82 g, 17.5 mmol) in dry DMF (50 mL) was addedsequentially DIEA (9.12 mL, 52.4 mmol) and 1-bromo-2-methoxyethane (1.97mL, 20.9 mmol). The mixture was stirred at ambient temperature for 46hours and then poured into H₂O (300 mL). The mixture was extracted withEtOAc (3×150 mL) and the combined extracts were washed with brine, driedover MgSO₄/activated carbon, filtered through a SiO₂ plug capped withpacked MgSO₄, and eluted with EtOAc. The solution was concentrated anddried in vacuo yielding the product as a white solid (5.15 g, 92%yield). MS (apci) m/z=321.1 (M+H).

Step B: Preparation oftrans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-amine dihydrochloride

To a solution of tert-butyltrans-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-ylcarbamate (5.10 g, 15.9mmol) in 2:1 EtOAc-MeOH (150 mL) was added 4 N HCl in dioxane (59.7 mL,239 mmol). The mixture was stirred at ambient temperature for 90 minutesand then concentrated in vacuo. The resulting foam was treated withEtOAc (200 mL), sonicated for 5 minutes and stirred vigorously until afine white suspension formed. The suspension was filtered, washed withEtOAc and dried under vacuum to afford the title compound as a whitepowder (5.10 g, 100% yield). MS (apci) m/z=221.1 (M+H).

Preparation D-100

(3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-amine dihydrochlorideStep A: Preparation of (R)-3-cinnamoyl-4-phenyloxazolidin-2-one

A THF (50 mL) solution of (R)-4-phenyloxazolidin-2-one (5.90 g, 36.2mmol) was cooled to −78° C. and treated with lithiumbis(trimethylsilyl)amide (36.9 mL, 36.9 mmol, 1.0 M in THF) dropwiseover 15 minutes. After 15-minute stirring at −78° C., a THF (10 mL)solution of cinnamoyl chloride (6.33 g, 38.0 mmol) was then introduced.The mixture was stirred for 1 hour at −78° C. and 2 hours at ambienttemperature before it was quenched with saturated NaHCO₃ (50 mL) andstirred for 1 hour. The mixture was diluted with EtOAc (200 mL), washedwith water and brine, dried over MgSO₄, filtered and concentrated togive the product as a pale yellow solid (10.6 g, 99.9% yield). MS (apci)m/z=293.9 (M+H).

Step B: Preparation of(R)-3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidine-3-carbonyl)-4-phenyloxazolidin-2-one

A toluene (500 mL) solution of (R)-3-cinnamoyl-4-phenyloxazolidin-2-one(8.00 g, 27.3 mmol) and TFA (0.210 mL, 2.73 mmol) was first cooled to5-10° C., followed by dropwise addition of a toluene (30 mL) solution of2-methoxy-N-(methoxymethyl)-N-((trimethylsilyl)methyl)ethanamine(Preparation C, 8.40 g, 40.9 mmol). The resulting mixture was warmed upto ambient temperature and stirred for 3 hours, then washed withsaturated NaHCO₃ and water, dried with MgSO₄, filtered and concentratedin vacuo. The crude material was purified by silica columnchromatography, eluting with 16-20% EtOAc/hexanes, to afford the product(6.5 g, 60% yield). MS (apci) m/z=395.2 (M+H).

Step C: Preparation of(3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidine-3-carboxylic acid

To a 1M aqueous solution of LiOH (41.2 mL, 41.2 mmol) at 0° C. was addedH₂O₂ (3.37 mL, 33.0 mmol, 30 wt %). The mixture was then added tosolution of(R)-3-((3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidine-3-carbonyl)-4-phenyloxazolidin-2-one(6.50 g, 16.5 mmol) in THF (100 mL) over 10 minutes at 0° C. After 1hour stirring, 2.0 M aqueous Na₂SO₃ (33.0 mL, 65.9 mmol) was introducedat 0° C. and the reaction mixture was warmed to ambient temperature.After stirring for 10 minutes, the mixture was washed with EtOAc (50mL). The aqueous layer was acidified with 1 N HCl until pH 3-5, thentreated with NaCl (10 g), then extracted with 10% iPrOH/DCM. The organiclayer was dried with MgSO₄, filtered and concentrated to give theproduct (4.11 g, 100% yield). MS (apci) m/z=250.1 (M+H).

Step D: Preparation of benzyl(3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-ylcarbamate

To a solution of(3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidine-3-carboxylic acid (4.11g, 16.5 mmol) in toluene (70 mL) was added TEA (5.74 mL, 41.2 mmol)followed by diphenyl phosphoryl azide (4.99 mL, 23.1 mmol). The mixturewas stirred at ambient temperature for 1 hour and then heated to refluxfor 1 hour. Benzyl alcohol (3.42 mL, 33.0 mmol) was then added and thereaction mixture was refluxed for 15 hours. The reaction mixture wastreated with EtOAc, washed with water, dried over MgSO₄, filtered andconcentrated in vacuo. The crude material was purified by silica columnchromatography, eluting with 1% MeOH/DCM to afford the product (2.5 g,43% yield). MS (apci) m/z=355.2 (M+H).

Step E: Preparation of(3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-amine dihydrochloride

Benzyl (3S,4R)-1-(2-methoxyethyl)-4-phenylpyrrolidin-3-ylcarbamate(0.257 g, 0.725 mmol) and TFA (3.91 mL, 50.8 mmol) were heated at 60° C.for 17 hours. The reaction mixture was concentrated in vacuo, usingtoluene to azeotrope, then treated with 2 N HCl in Et₂O and concentratedagain to give the title compound (0.21 g, 100% yield) as an off-whitesolid. MS (apci) m/z=221.2 (M+H).

Preparation E-100

(3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-aminetrifluoroacetate Step A: Preparation of(R,E)-3-(3-(3,5-difluorophenyl)acryloyl)-4-phenyloxazolidin-2-one

To a solution of (E)-3-(3,5-difluorophenyl)acrylic acid (10.0 g, 54.3mmol) in Et₂O (150 mL) at 0° C. was added DIEA (9.48 mL, 54.3 mmol)followed by pivaloyl chloride (6.69 mL, 54.3 mmol). The mixture wasstirred at 0° C. for 1 hour and cooled to −78° C. Meanwhile(R)-4-phenyloxazolidin-2-one (8.86 g, 54.3 mmol) in THF (200 mL) wascooled to −78° C. and butyllithium (21.7 mL, 2.5 M, 54.3 mmol) was addedslowly. The mixture was stirred for 20 minutes at −78° C. andtransferred by cannula to the solution of mixed anhydride. The combinedmixture was stirred at −78° C. for 15 min, allowed to warm to 0° C. andstirred for an additional 30 minutes. The reaction mixture was quenchedwith saturated NH₄Cl (25 mL), diluted with EtOAc (600 mL), washed withwater, NaHCO₃, and brine, dried over MgSO₄, and concentrated in vacuo.The crude material was purified by silica column chromatography, elutingwith 10-20% Ethyl acetate/Hexanes to afford the product (11.0 g, 61.5%yield).

Step B: Preparation of(3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-aminetrifluoroacetic acid salt

Prepared by the methods described in Preparation D-100, Steps B throughE, replacing (R)-3-cinnamoyl-4-phenyloxazolidin-2-one with(R,E)-3-(3-(3,5-difluorophenyl)acryloyl)-4-phenyloxazolidin-2-one toafford the title compound (1.70 g, 102% yield). MS (apci) m/z=257.2(M+H).

Preparation F-100

(3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine

Prepared according to the method described in Preparation D-100,replacing cinnamoyl chloride with (E)-3-(3,4-difluorophenyl)acryloylchloride. MS (apci) m/z=257.1 (M+H).

Preparation G-100

(3S,4R)-1-(2-methoxyethyl)-4-(3-(trifluoromethyl)phenyl)pyrrolidin-3-aminedihydrochloride Step A: Preparation of tert-butyl(3S,4R)-1-(2-methoxyethyl)-4-(3-(trifluoromethyl)-phenyl)pyrrolidin-3-ylcarbamate

A solution of tert-butyl(3S,4R)-4-(3-(trifluoromethyl)phenyl)-pyrrolidin-3-ylcarbamate (100 mg,0.303 mmol, commercially available), N,N-diethylpropan-2-amine (0.145mL, 0.908 mmol) and 1-bromo-2-methoxyethane (0.0361 mL, 0.363 mmol) inDMF (1 mL) was stirred at ambient temperature for 2 hours, then heatedto 60° C. for 4 hours, then cooled to ambient temperature overnight.After partitioning between EtOAc and saturated NaHCO₃ (10 mL each), theorganic layer was washed with water and brine (2×10 mL each), dried overNa₂SO₄, filtered and concentrated to yield the crude product as whitesolid (80 mg, 68% yield). LCMS (apci) m/z=389.1 (M+H).

Step B: Preparation of(3S,4R)-1-(2-methoxyethyl)-4-(3-(trifluoromethyl)phenyl)-pyrrolidin-3-aminedihydrochloride

A solution of tert-butyl(3S,4R)-1-(2-methoxyethyl)-4-(3-(trifluoromethyl)phenyl)pyrrolidin-3-ylcarbamate(80.0 mg, 0.206 mmol) in 5-6 N HCl in IPA (4.12 mL, 20.6 mmol) wasstirred at ambient temperature for 1 hour, followed by concentrating invacuo and triturating with Et₂O to afford the product as beige solid (74mg, 99.5% yield). LCMS (apci) m/z=289.1 (M+H).

Preparation 11-100

(3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-aminedihydrochloride

Prepared according to the method of Preparation G-100, replacingtert-butyl(3S,4R)-4-(3-(trifluoromethyl)phenyl)-pyrrolidin-3-ylcarbamate withtert-butyl (3S,4R)-4-(3-fluorophenyl)pyrrolidin-3-ylcarbamate to affordthe title compound. LCMS (apci) m/z=239.1 (M+H).

Preparation I-100

(3S,4R)-4-(2,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-aminedihydrochloride

Prepared according to the method of Preparation G-100, replacingtert-butyl(3S,4R)-4-(3-(trifluoromethyl)phenyl)-pyrrolidin-3-ylcarbamate withtert-butyl (3S,4R)-4-(2,4 di-fluoro-phenyl)pyrrolidin-3-ylcarbamate toafford the title compound. LCMS (apci) m/z=257.1 (M+H).

Preparation J-100

(3S,4R)-4-(2,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-aminedihydrochloride

Prepared according to the method of Preparation G-100, replacingtert-butyl(3S,4R)-4-(3-(trifluoromethyl)phenyl)-pyrrolidin-3-ylcarbamate withtert-butyl (3S,4R)-4-(2,5 di-fluoro-phenyl)pyrrolidin-3-ylcarbamate toafford the title compound. LCMS (apci) m/z=257.1 (M+H).

Preparation K-100

(3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-aminedihydrochloride

Prepared according to the method described in Preparation D-100,replacing cinnamoyl chloride with (E)-3-(4-fluorophenyl)acryloylchloride. MS (apci) m/z=239.1 (M+H).

The following pyrrolidine intermediates were made according to themethod of Preparation B1, Steps A-C, using the appropriate benzaldehydein Step A and replacing EtOH and platinum(IV) oxide with MeOH and Raneynickel respectively in Step C.

Preparation # Structure Name Data L-101

trans-4-(2,4- difluorophenyl)-1-(2- methoxyethyl)pyrrolidin- 3-amine MS(apci) m/z = 256.1 (M + H) L-102

trans-4-(5-fluoropyridin- 3-yl)-1-(2- methoxyethyl)pyrrolidin- 3-amineMS (apci) m/z = 240.1 (M + H) L-103

trans-4-(5-fluoropyridin- 2-yl)-1-(2- methoxyethyl)pyrrolidin- 3-amine¹H NMR consistent with expected product L-104

trans-4-(3-fluoropyridin- 4-yl)-1-(2- methoxyethyl)pyrrolidin- 3-amineNot available L-105

trans-4-(5-chloropyridin- 3-yl)-1-(2- methoxyethyl)pyrrolidin- 3-amineMS (apci) m/z = 256.1 (M + H) L-106

trans-1-(2- methoxyethyl)-4-(1- methyl-1H-pyrazol-4-yl)pyrrolidin-3-amine ¹H NMR consistent with expected product L-107

trans-1-(2- methoxyethyl)-4-(1,2,3- thiadiazol-4- yl)pyrrolidin-3-amineNot available

Preparation L-108

4-(trans-4-amino-1-(2-methoxyethyl)pyrrolidin-3-yl)benzonitrile

Prepared according to the method described in Preparation B1, Steps A toC, replacing 4-fluorobenzaldehyde with 4-formylbenzonitrile in Step Aand replacing EtOH and platinum(IV) oxide with MeOH, Zn (dust) andsaturated NH₄Cl, respectively in Step C. MS (apci) m/z=246.1 (M+H).

Preparation L-109

3-(trans-4-amino-1-(2-methoxyethyl)pyrrolidin-3-yl)benzonitrile

Prepared according to the method described in Preparation B1, Steps A toC, replacing 4-fluorobenzaldehyde with 3-formylbenzonitrile in Step A,and replacing EtOH and platinum(IV) oxide with MeOH, Zn (dust) andsaturated NH₄Cl, respectively, in Step C. MS (apci) m/z=246.2 (M+H).

Preparation N-100

Trans-5-(4-amino-1-(2-methoxyethyl)pyrrolidin-3-yl)-2-fluorobenzonitrileStep A: (E)-2-fluoro-5-(2-nitrovinyl)benzonitrile

To a solution of 2-fluoro-5-formylbenzonitrile (3.84 g, 25.0 mmol) in3:1 CH₃NO₂/CH₃CN (25 mL) was added DMAP (0.305 g, 2.50 mmol) and themixture stirred at ambient temperature for 23 hours. The mixture wascooled on an ice bath and Ac₂O (3.54 mL, 37.5 mmol) was added. Themixture was stirred for 5 minutes, allowed to reach ambient temperatureand stirred for 1 hour. The mixture was concentrated to a yellow solid.The solid was suspended in iPrOH (70 mL) and stirred for 10 minutes. Thesuspension was collected via vacuum filtration, the cake washed withiPrOH and dried in vacuum to afford the title compound as a light tanpowder (3.36 g, 70%). ¹H NMR (CDCl₃) δ 7.96 (d, 1H), 7.79-7.88 (m, 2H),7.57 (d, 1H), 7.36 (t, 1H).

Step B:Trans-2-fluoro-5-(1-(2-methoxyethyl)-4-nitropyrrolidin-3-yl)benzonitrile

Using (E)-2-fluoro-5-(2-nitrovinyl)benzonitrile in Step B of theprocedure describe in Preparation B1, the title compound was prepared aslight gold syrup (1.56 g, 53%). MS (apci) m/z=294.1 (M+H).

Step C:Trans-5-(4-amino-1-(2-methoxyethyl)pyrrolidin-3-yl)-2-fluorobenzonitrile

A solution oftrans-2-fluoro-5-(1-(2-methoxyethyl)-4-nitropyrrolidin-3-yl)benzonitrile(450 mg, 1.53 mmol) in MeOH (6.0 mL) was cooled to 0°. Zn dust (1.00 mg,15.3 mmol) and saturated aqueous NH₄Cl (1.0 mL) were added sequentiallyand the mixture was stirred for 5 minutes. The mixture was allowed toreach ambient temperature and stirred until complete by LCMS analysis.The mixture was filtered through packed Celite® using MeOH for rinsingand elution and the filtrate was concentrated to a colorless syrup. Thesyrup was treated with 1M K₂CO₃ (15 mL), mixed and extracted with CH₂Cl₂(3×). The combined CH₂Cl₂ extracts were dried over Na₂SO₄, filtered andconcentrated to provide the title compound as a colorless syrup (412 mg,100%). MS (apci) m/z=264.1 (M+H).

Preparation O-100

Trans-3-(4-amino-1-(2-methoxyethyl)pyrrolidin-3-yl)-5-fluorobenzonitrileStep A: 3-fluoro-5-formylbenzonitrile

A solution of 3-bromo-5-fluorobenzonitrile (5.00 g, 25.0 mmol) in dryTHF (25 mL) was cooled to 0° C. and 2M iPrMgCl (15.0 mL, 30.0 mmol) inTHF was added dropwise over 5 minutes. The mixture was stirred at 0° C.for 15 minutes then at ambient temperature for 1 hour. The mixture wascooled to 0° C. and dry DMF (5.81 mL, 75.0 mmol) was added. The mixturewas stirred for 17 hours during which time the temperature reachedambient temperature after 2 hours. The mixture was added to ice water(150 mL) and Et₂O (100 mL). The biphasic mixture was stirred and treatedwith 6M HCl to aqueous pH=3. The organic layer was removed and theaqueous layer extracted with Et₂O (2×). The combined Et₂O fractions werewashed with saturated NaCl and dried over MgSO₄/activated carbon. Thedried solution was filtered through a SiO₂ plug eluting with Et₂O. Thefiltrate was concentrated to give the title compound as a yellow solidthat was dried in vacuum (3.68 g, 99%). ¹H NMR (CDCl₃) δ 10.0 (s, 1H),8.00 (s, 1H), 7.81-7.86 (m, 1H), 7.62-7.67 (m, 1H).

Step B:Trans-3-(4-amino-1-(2-methoxyethyl)pyrrolidin-3-yl)-5-fluorobenzonitrile

The tile compound was prepared using 3-fluoro-5-formylbenzonitrile inthe procedure described for the preparation oftrans-5-(4-amino-1-(2-methoxyethyl)pyrrolidin-3-yl)-2-fluorobenzonitrile(Preparation N-100). The compound was isolated as a colorless syrup (542mg, 93%). MS (apci) m/z=264.1 (M+H).

Preparation P-100

Trans-1-(2-methoxyethyl)-4-(4-chlorophenyl)pyrrolidin-3-amine Step A:Trans-3-(4-chlorophenyl)-1-(2-methoxyethyl)-4-nitropyrrolidine

Using (E)-1-chloro-4-(2-nitrovinyl)benzene in Step B of the proceduredescribe in Preparation B1, the title compound was prepared as viscouscolorless oil (5.10 g, 64%). MS (apci) m/z=285.0 (M+H).

Step B: Trans-1-(2-methoxyethyl)-4-(4-chlorophenyl)pyrrolidin-3-amine

To a suspension of 2800 Raney Nickel (50 wt % in H₂O, 0.873 g, 5.10mmol) in MeOH (25 mL) was addedtrans-3-(4-chlorophenyl)-1-(2-methoxyethyl)-4-nitropyrrolidine (2.90 g,10.2 mmol) in MeOH (25 mL). The mixture was flushed with H₂ gas andstirred under a balloon atmosphere of H₂ for 16 hours. The mixture waspurged with N₂ gas and filtered through packed Celite® using MeOH forrinsing and elution. The filtrate was concentrated to a cloudy oil. Theoil was dissolved in CH₂Cl₂ and dried over Na₂SO₄/activated carbon. Thesolution was filtered and concentrated to provide the title compound asa light gold oil that was dried in vacuum (2.46 g, 95%). MS (apci)m/z=255.1 (M+H).

Preparation E

5-amino-4-methyl-1-phenyl-1H-pyrazol-3-yl trifluoromethanesulfonate StepA: Preparation of 5-amino-4-methyl-1-phenyl-1H-pyrazol-3(2H)-one

A mixture of ethyl 2-cyanopropanoate (50.5 g, 397.2 mmol) andphenylhydrazine (39 mL, 397.2 mmol) in dioxane (100 mL) was heated at110° C. for 5 days. The cooled mixture was concentrated to ½ volume thencooled in ice and triturated with cold Et₂O. Solids were filtered,washed extensively with Et₂O and dried in vacuo to afford5-amino-4-methyl-1-phenyl-1H-pyrazol-3(2H)-one (34.69 g, 46% yield) as afluffy white powder. MS (apci) m/z=190.1 (M+H).

Step B: Preparation of 5-amino-4-methyl-1-phenyl-1H-pyrazol-3-yltrifluoromethane sulfonate

A suspension of 5-amino-4-methyl-1-phenyl-1H-pyrazol-3(2H)-one (13.72 g,72.5 mmol) and N-phenylbis(trifluoromethylsulfonamide) (27.2 g, 76.1mmol) in DMF (100 mL) was treated with DIEA (37.9 mL, 217.5 mmol) andthe mixture stirred at ambient temperature for 16 hours. The mixture waspartitioned between saturated NaHCO₃ (400 mL) and EtOAc (200 mL) and theaqueous layer was extracted with EtOAc (2×200 mL). The combined organicphases were washed with water (5×50 mL) and brine (50 mL) then driedover Na₂SO₄, filtered and concentrated in vacuo. The residue waspurified by silica column chromatography eluting with 4:1 hexanes/EtOAc,to afford the title compound (23.1 g, 99% yield) as a pale yellow solid.MS (apci) m/z=322.0 (M+H).

Preparation F

3-bromo-4-methyl-1-phenyl-1H-pyrazol-5-amine

To a suspension of 5-amino-4-methyl-1-phenyl-1H-pyrazol-3(2H)-one[Preparation E, step A] (1.60 g, 8.46 mmol) in acetonitrile (30 mL) wasadded phosphorus oxybromide (3.64 g, 12.7 mmol) in one portion. Themixture was stirred at reflux for 3 hours then cooled and concentratedin vacuo. The residue was treated with DCM (50 mL) then saturated NaHCO₃(50 mL) was slowly added. The mixture was stirred for 30 minutes thenthe layers separated and the aqueous layer extracted with DCM (2×50 mL).The combined organic phases were washed with brine (20 mL), dried overNa₂SO₄, filtered and concentrated in vacuo. The residue was purified bysilica column chromatography eluting with 2:1 hexanes/EtOAc, to affordthe title compound (273 mg, 13% yield) as a white solid. MS (apci)m/z=254.0 (M+H).

Preparation G

5-(5-amino-4-methyl-1-phenyl-1H-pyrazol-3-yl)-1-methylpyridin-2 (1H)-one

3-bromo-4-methyl-1-phenyl-1H-pyrazol-5-amine [Preparation F] (763 mg,3.03 mmol),1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)one(1.42 g, 6.05 mmol), K₂CO₃ (1.67 g, 12.1 mmol) and Pd(PPh₃)₄ (350 mg,0.30 mmol) were combined in toluene (10 mL), water (5 mL) and EtOH (2.5mL) and warmed to 95° C. in a sealed tube for 16 hours. The cooledmixture was filtered and the filtrate partitioned between water (30 mL)and EtOAc (30 mL). The aqueous layer was extracted with EtOAc (2×20 mL)and the combined organic phases were washed with brine (20 mL), driedover Na₂SO₄, filtered and concentrated in vacuo. The residue waspurified by silica column chromatography eluting with 2% MeOH/DCM toafford the title compound (504 mg, 59% yield) as a yellow foam. MS(apci) m/z=281.2 (M+H).

Preparation H

phenyl(4-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-phenyl-1H-pyrazol-5-yl)carbamate

To a suspension of5-(5-amino-4-methyl-1-phenyl-1H-pyrazol-3-yl)-1-methylpyridin-2(1H)-one[Preparation G] (2.80 g, 9.99 mmol) in EtOAc (120 mL) was added 2N NaOH(14.98 mL, 29.97 mmol) followed by phenyl chloroformate (2.5 mL, 19.98mmol). The mixture was stirred at ambient temperature for 16 hours thenpartitioned between water (100 mL) and EtOAc (100 mL) and the aqueouslayer extracted with EtOAc (2×50 mL). The combined organic phases werewashed with saturated NaHCO₃ (50 mL) and brine (50 mL), then dried overNa₂SO₄, filtered and concentrated to afford the title compound as a paleyellow syrup which was used directly without purification, assuming 100%yield. MS (apci) m/z=401.2 (M+H).

SYNTHETIC EXAMPLES Example 1

1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(6-methylpyridin-3-yl)-1-phenyl-1H-pyrazol-5-yl)ureaStep A: Preparation of4-methyl-3-(6-methylpyridin-3-yl)-1-phenyl-1H-pyrazol-5-amine

5-Amino-4-methyl-1-phenyl-1H-pyrazol-3-yl trifluoromethane sulfonate[Preparation E] (1.01 g, 3.11 mmol), (6-methylpyridin-3-yl)boronic acid(639 mg, 4.67 mmol), K₂CO₃ (1.72 g, 12.45 mmol) and Pd(PPh₃)₄ (360 mg,0.31 mmol) were combined in toluene (10 mL), water (5 mL) and EtOH (2.5mL) and stirred at 95° C. in a sealed tube for 18 hours. The cooledmixture was filtered through GF paper and the filtrate partitionedbetween water (50 mL) and EtOAc (50 mL). The aqueous layer was extractedwith EtOAc (2×30 mL) and the combined organic phases were washed withbrine (30 mL), dried over Na₂SO₄, filtered and concentrated in vacuo.The residue was purified by silica column chromatography eluting with 2%MeOH/DCM to afford4-methyl-3-(6-methylpyridin-3-yl)-1-phenyl-1H-pyrazol-5-amine (529 mg,64% yield) as a red solid. MS (apci) m/z=265.1 (M+H).

Step B: Preparation of1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(6-methylpyridin-3-yl)-1-phenyl-1H-pyrazol-5-yl)urea

To a solution of4-methyl-3-(6-methylpyridin-3-yl)-1-phenyl-1H-pyrazol-5-amine (40 mg,0.15 mmol) in DCM (2 mL) was added triphosgene (22 mg, 0.07 mmol)followed by DIEA (79 μL, 0.46 mmol). The solution was stirred for 30minutes at ambient temperature then treated with(3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine[Preparation B3] (50 mg, 0.15 mmol) and DIEA (79 ΞL, 0.46 mmol). Afterstirring at ambient temperature for 16 hours the mixture was partitionedbetween saturated NH₄Cl (10 mL) and DCM (10 mL) and the aqueous layerextracted with DCM (2×10 mL). The combined organic phases were washedwith brine (10 mL), dried over Na₂SO₄, filtered and concentrated invacuo. The residue was purified by silica column chromatography elutingwith 2.5-5% MeOH/DCM to afford the title compound (63 mg, 76% yield) asa pale yellow solid. MS (apci) m/z=547.2 (M+H).

Example 2

1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyridin-4-yl)-1-phenyl-1H-pyrazol-5-yl)urea

Prepared according to the procedure of Example 1, replacing(6-methylpyridin-3-yl)boronic acid with (2-methylpyridin-4-yl)boronicacid in Step A. The crude material was purified by silica columnchromatography eluting with 3-5% MeOH/DCM, then reverse phase HPLC(5-95% ACN/water/0.1% TFA) to afford the title compound (27 mg, 16%yield) as a white solid. MS (apci) m/z=547.3 (M+H).

Example 3

1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(2-fluoropyridin-3-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea

Prepared according to the procedure of Example 1, replacing(6-methylpyridin-3-yl)boronic acid with (2-fluoropyridin-3-yl)boronicacid in Step A. The crude material was purified by silica columnchromatography eluting with 1-2.5% MeOH/DCM to afford the title compound(69 mg, 75% yield) as a cream solid. MS (apci) m/z=551.2 (M+H).

Example 4

1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyridin-3-yl)-1-phenyl-1H-pyrazol-5-yl)urea

Prepared according to the procedure of Example 1, replacing(6-methylpyridin-3-yl)boronic acid with (2-methylpyridin-3-yl)boronicacid in Step A. The crude material was purified by silica columnchromatography eluting with 2-5% MeOH/DCM to afford the title compound(70 mg, 68% yield) as a colorless gum. MS (apci) m/z=547.3 (M+H).

Example 5

1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(5-methylpyridin-3-yl)-1-phenyl-1H-pyrazol-5-yl)urea

Prepared according to the procedure of Example 1, replacing(6-methylpyridin-3-yl)boronic acid with (5-methylpyridin-3-yl)boronicacid in Step A. The crude material was purified by silica columnchromatography eluting with 2.5% MeOH/DCM to afford the title compound(51 mg, 49% yield) as a white solid. MS (apci) m/z=547.2 (M+H).

Example 6

1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(5-methoxypyridin-3-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea

Prepared according to the procedure of Example 1, replacing(6-methylpyridin-3-yl)boronic acid with (5-methoxypyridin-3-yl)boronicacid in Step A. The crude material was purified by silica columnchromatography eluting with 2.5% MeOH/DCM to afford the title compound(51 mg, 49% yield) as a white solid. MS (apci) m/z=547.2 (M+H).

Example 7

1-(3-(5-cyanopyridin-3-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea

Prepared according to the procedure of Example 1, replacing(6-methylpyridin-3-yl)boronic acid with5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinonitrile in StepA. The crude material was purified by silica column chromatographyeluting with 2% MeOH/DCM to afford the title compound (70 mg, 69% yield)as a pale pink solid. MS (apci) m/z=558.2 (M+H).

Example 8

1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(6-methoxypyridin-3-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea

Prepared according to the procedure of Example 1, replacing(6-methylpyridin-3-yl)boronic acid with (6-methoxypyridin-3-yl)boronicacid in Step A. The crude material was purified by silica columnchromatography eluting with 2.5% MeOH/DCM to afford the title compound(31 mg, 31% yield) as a white solid. MS (apci) m/z=563.3 (M+H).

Example 9

1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(2-ethoxypyrimidin-5-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea

Prepared according to the procedure of Example 1, replacing(6-methylpyridin-3-yl)boronic acid with (2-ethoxypyrimidin-5-yl)boronicacid in Step A. The crude material was purified by silica columnchromatography eluting with 2-4% MeOH/DCM to afford the title compound(42 mg, 43% yield) as a white solid. MS (apci) m/z=578.3 (M+H).

Example 10

1-(3-(2-cyclopropylpyrimidin-5-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea

Prepared according to the procedure of Example 1, replacing(6-methylpyridin-3-yl)boronic acid with2-cyclopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidinein Step A. The crude material was purified by silica columnchromatography eluting with 2.5-5% MeOH/DCM to afford the title compound(38 mg, 39% yield) as a pale yellow solid. MS (apci) m/z=574.3 (M+H).

Example 11

1-(3-(2-cyclopropylpyrimidin-5-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea

Prepared according to the procedure of Example 10, replacing(3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine[Preparation B3] with(3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine[Preparation B1] in Step B. The crude material was purified by silicacolumn chromatography eluting with 2.5-5% MeOH/DCM to afford the titlecompound (44 mg, 47% yield) as a pale yellow solid. MS (apci) m/z=556.3(M+H).

Example 12

1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(2-methoxypyrimidin-5-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea

Prepared according to the procedure of Example 1, replacing(6-methylpyridin-3-yl)boronic acid with (2-methoxypyrimidin-5-yl)boronicacid in Step A and(3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine[Preparation B3] with(3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine[Preparation B2] in Step B. The crude material was purified by silicacolumn chromatography eluting with 2.5-5% MeOH/DCM to afford the titlecompound (21 mg, 25% yield) as a cream solid. MS (apci) m/z=564.2 (M+H).

Example 13

1-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1H-pyrazol-5-yl)urea

Prepared according to the procedure of Example 1, replacing(6-methylpyridin-3-yl)boronic acid with2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine inStep A and(3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine[Preparation B3] with(3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine[Preparation B1] in Step B. The crude material was purified by silicacolumn chromatography eluting with 3-5% MeOH/DCM to afford the titlecompound (49 mg, 44% yield) as a pale yellow solid. MS (apci) m/z=530.2(M+H).

Example 14

1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1H-pyrazol-5-yl)urea

Prepared according to the procedure of Example 13, replacing(3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine[Preparation B3] with(3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine[Preparation B2] in Step B. The crude material was purified by silicacolumn chromatography eluting with 3-5% MeOH/DCM to afford the titlecompound (34 mg, 41% yield) as a cream solid. MS (apci) m/z=548.2 (M+H).

Example 15

1-(3-(2-ethoxypyrimidin-5-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea

Prepared according to the procedure of Example 9, replacing(3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine[Preparation B3] with(3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine[Preparation B1] in Step B. The crude material was purified by silicacolumn chromatography eluting with 2.5% MeOH/DCM to afford the titlecompound (20 mg, 33% yield) as a white solid. MS (apci) m/z=560.3 (M+H).

Example 16

1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(2-ethoxypyrimidin-5-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea

Prepared according to the procedure of Example 9, replacing(3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine[Preparation B3] with(3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine[Preparation B2] in Step B. The crude material was purified by silicacolumn chromatography eluting with 2.5% MeOH/DCM to afford the titlecompound (16 mg, 26% yield) as a white solid. MS (apci) m/z=578.3 (M+H).

Example 17

1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-1-phenyl-1H-pyrazol-5-yl)urea

Prepared according to the procedure of Example 1, replacing(6-methylpyridin-3-yl)boronic acid with2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridazin-3(2H)-onein Step A. The crude material was purified by silica columnchromatography eluting with 2-3% MeOH/DCM to afford the title compound(48 mg, 48% yield) as a white solid. MS (apci) m/z=564.3 (M+H).

Example 18

1-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-1-phenyl-1H-pyrazol-5-yl)urea

Prepared according to the procedure of Example 17, replacing(3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine[Preparation B3] with(3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine[Preparation B1] in Step B. The crude material was purified by silicacolumn chromatography eluting with 2.5-4% MeOH/DCM to afford the titlecompound (32 mg, 41% yield) as a cream solid. MS (apci) m/z=546.2 (M+H).

Example 19

1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-1-phenyl-1H-pyrazol-5-yl)urea

Prepared according to the procedure of Example 17, replacing(3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine[Preparation B3] with(3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine[Preparation B2] in Step B. The crude material was purified by silicacolumn chromatography eluting with 2.5% MeOH/DCM to afford the titlecompound (25 mg, 31% yield) as a white solid. MS (apci) m/z=564.2 (M+H).

Example 20

1-(3-(2-(cyclopropylamino)pyrimidin-5-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)ureaStep A: Preparation of phenyl(3-bromo-4-methyl-1-phenyl-1H-pyrazol-5-yl)carbamate

To a solution of 3-bromo-4-methyl-1-phenyl-1H-pyrazol-5-amine[Preparation F] (339 mg, 1.34 mmol) in EtOAc (10 mL) was added 2N NaOH(2 mL, 4.0 mmol) followed by phenyl chloroformate (337 μL, 2.69 mmol).The mixture was stirred at ambient temperature for 5 hours thenpartitioned between water (30 mL) and EtOAc (30 mL) and the aqueouslayer extracted with EtOAc (2×20 mL). The combined organic phases werewashed with saturated NaHCO₃ (30 mL) and brine (30 mL), then dried overNa₂SO₄, filtered and concentrated in vacuo to afford phenyl(3-bromo-4-methyl-1-phenyl-1H-pyrazol-5-yl)carbamate which was useddirectly in the next step, assuming quantitative yield. MS (apci)m/z=374.0 (M+H).

Step B: Preparation of1-(3-bromo-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea

To a solution of(3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine[Preparation B3] (464 mg, 1.41 mmol) and phenyl(3-bromo-4-methyl-1-phenyl-1H-pyrazol-5-yl)carbamate (500 mg, 1.34 mmol)in DCM (10 mL) was added DIEA (819 μL, 4.7 mmol). The solution wasstirred at ambient temperature for 18 hours. The reaction mixture waspartitioned between saturated NH₄Cl (30 mL) and DCM (30 mL) and theaqueous layer was extracted with DCM (2×20 mL). The combined organicphases were washed with brine (20 mL), dried over Na₂SO₄, filtered andconcentrated in vacuo. The residue was purified by silica columnchromatography eluting with 2% MeOH/DCM to afford1-(3-bromo-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea(483 mg, 67% yield) as a white solid. MS (apci) m/z=534.1 (M+).

Step C:1-(3-(2-(cyclopropylamino)pyrimidin-5-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea

1-(3-Bromo-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea (100 mg, 0.19 mmol),N-cyclopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine(147 mg, 0.56 mmol) and tricyclohexyl phosphine (11 mg, 0.04 mmol) werecombined in 1,4-dioxanes (3 mL) and purged with Argon for 5 minutes.Pd₂ba₃ (17 mg, 0.02 mmol) and K₃PO₄ (432 μL, 1.3M, 0.56 mmol) were addedand the mixture purged with Argon for a further 30 seconds then sealedand stirred at 100° C. for 16 hours. The cooled mixture was filtered andthe filtrate was partitioned between water (20 mL) and EtOAc (20 mL).The aqueous layer was extracted with EtOAc (2×10 mL) and the combinedorganic phases were washed with brine (10 mL), dried over Na₂SO₄,filtered and concentrated in vacuo. The residue was purified by silicacolumn chromatography eluting with 2.5-5% MeOH/DCM, then triturated withDCM, filtered and the filtrate concentrated to afford the title compound(14 mg, 13% yield) as a pale yellow solid. MS (apci) m/z=589.3 (M+H).

Example 21

1-(3-(2-(cyclopropylamino)pyrimidin-5-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)ureadi-trifluoroacetate

Prepared according to the procedure of Example 20, replacing(3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine[Preparation B3] with(3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine[Preparation B1] in Step B. The crude material was purified by silicacolumn chromatography eluting with 2.5-5% MeOH/DCM then reverse phaseHPLC (5-95% ACN/water/0.1% TFA) to afford the title compound (26 mg, 17%yield) as a di-TFA salt as a colorless glass. MS (apci) m/z=571.3 (M+H).

Example 22

1-(trans-4-(3-chloro-4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-phenyl-1H-pyrazol-5-yl)urea

To a solution oftrans-4-(3-chloro-4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine(Preparation B4, 12.7 mg, 0.0467 mmol) in DCM (1 mL) was added DIEA(0.016 mL, 0.093 mmol), followed by the addition of phenyl4-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-phenyl-1H-pyrazol-5-ylcarbamate(Preparation H, 18.7 mg, 0.047 mmol). The reaction mixture was stirredat ambient temperature for 1 hour, then purified by reverse-phase columnchromatography, eluting with 0-70% acetonitrile/water, to afford thetitle compound (15 mg, 56% yield) as a pale yellow solid. MS (apci)m/z=579.2 (M+H).

Example 23

1-(trans-4-(4-chloro-3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-phenyl-1H-pyrazol-5-yl)urea

Prepared according to the procedure of Example 22, replacingtrans-4-(3-chloro-4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-aminewithtrans-4-(4-chloro-3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine[Preparation B5]. The reaction mixture was purified by reverse-phasecolumn chromatography, eluting with 0-70% acetonitrile/water, to affordthe title compound (16 mg, 60% yield) as a pale yellow solid. MS (apci)m/z=579.2 (M+H).

Example 24

1-(trans-4-(3-chloro-5-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-phenyl-1H-pyrazol-5-yl)urea

Prepared according to the procedure of Example 22, replacingtrans-4-(3-chloro-4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-aminewithtrans-4-(3-chloro-5-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine[Preparation B6]. The reaction mixture was purified by reverse-phasecolumn chromatography, eluting with 0-70% acetonitrile/water, to affordthe title compound (17 mg, 63% yield) as a pale yellow solid. MS (apci)m/z=579.2 (M+H).

Example 25

1-(trans-4-(3-chlorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-phenyl-1H-pyrazol-5-yl)urea

Prepared according to the procedure of Example 22, replacingtrans-4-(3-chloro-4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-aminewith trans-4-(3-chlorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine[Preparation B7]. The reaction mixture was purified by reverse-phasecolumn chromatography, eluting with 0-70% acetonitrile/water, to affordthe title compound (15 mg, 57% yield) as a white solid. MS (apci)m/z=561.2 (M+H).

Example 26

1-((3S,4R)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-yl)-3-(4-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-phenyl-1H-pyrazol-5-yl)urea

A solution of triphosgene (23.1 mg, 0.0740 mmol) in dry CH₃CN (1 mL) wascooled to 0° C. and a solution of(3S,4R)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-aminedihydrochloride (Preparation C, 76.4 mg, 0.220 mmol) and DIEA (115 μL,0.660 mmol) in dry CH₃CN (0.5 mL) was added dropwise over 45 minutes.The mixture was stirred for 1 hour during which time temperature reached15° C.5-(5-Amino-4-methyl-1-phenyl-1H-pyrazol-3-yl)-1-methylpyridin-2(1H)-one(Preparation G, 56.1 mg, 0.200 mmol) was added in one portion and themixture was stirred at ambient temperature for 7 hours followed byheating at 40° C. for 17 hours. The reaction mixture was cooled toambient temperature and was diluted with chilled H₂O (4 mL) withthorough mixing. The cold mixture (pH=5) was treated with 2M NaOH topH=10 and was extracted with EtOAc (3×). The combined extracts werewashed with H₂O and saturated NaCl (2×). The EtOAc solution was driedover MgSO₄ and eluted through a short SiO₂ column eluting with EtOAc,10% MeOH/EtOAc then 10% (9:1/CH₃OH—NH₄OH)/EtOAc. The product-containingpool was concentrated to a colorless glass. The glass was treated withEt₂O and agitated until white suspension formed. The solvent wasdecanted and the residual solid was washed with Et₂O (2×) and dried invacuo to afford the title compound as a white solid (34 mg, 29% yield).MS (apci) m/z=581.2 (M+H).

Example 27

1-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-phenyl-1H-pyrazol-5-yl)urea

A mixture of phenyl 4-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-phenyl-1H-pyrazol-5-ylcarbamate (Preparation H,60.1 mg, 0.150 mmol) and(3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-aminedihydrochloride (Preparation D, 51.4 mg, 0.165 mmol) in DCM (1.0 mL) wastreated with DIEA (86.3 μL, 0.495 mmol). The mixture was stirred atambient temperature for 3 hours and was diluted with DCM (3 mL). Thediluted reaction mixture was washed with H₂O (2×), 1M NaOH (2×) and H₂Oand dried over Na₂SO₄/activated carbon. The solution was filtered,concentrated and the residue purified by silica column chromatography(EtOAc, 5% MeOH/EtOAc, 10% (9:1 MeOH/NH₄OH)/EtOAc step gradientelution). The resulting colorless glass was treated with Et₂O andagitated until a white granular suspension formed. The suspension wasfiltered, the solid washed with Et₂O and dried in vacuo to furnish thetitle compound as a white solid (46 mg, 56% yield). MS (apci) m/z=545.2(M+H).

Example 28

1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(1-methyl-2-oxo-1,2-dihydropyrimidin-5-yl)-1-phenyl-1H-pyrazol-5-yl)ureaStep A: Preparation of5-(5-amino-4-methyl-1-phenyl-1H-pyrazol-3-yl)pyrimidin-2(1H)-onehydrochloride

A solution of3-(2-methoxypyrimidin-5-yl)-4-methyl-1-phenyl-1H-pyrazol-5-amine[Prepared as in 1, Step A] (200 mg, 0.71 mmol) in methanol (5 mL) wastreated with 5-6 N HCl/isopropyl alcohol (5 mL) and stirred at refluxfor 4 hours. The mixture was cooled to ambient temperature and theresulting solid filtered, washed with methanol and dried in vacuo toafford 3-(2-methoxypyrimidin-5-yl)-4-methyl-1-phenyl-1H-pyrazol-5-amine(152 mg, 72% yield) as a pale yellow powder. MS (apci) m/z=268.1 (M+H).

Step B: Preparation of 5-(5-amino-4-methyl-1-phenyl-1H-pyrazol-3-yl)-1-methylpyrimidin-2(1H)-one

A solution of3-(2-methoxypyrimidin-5-yl)-4-methyl-1-phenyl-1H-pyrazol-5-amine (50 mg,0.16 mmol) DMA (1 mL) was treated with Cs₂CO₃ (161 mg, 0.49 mmol) andstirred at ambient temperature for 30 minutes. Methyl iodide (20 μL,0.33 mmol) was then added and the mixture stirred, capped, at ambienttemperature for 16 hours. The mixture was partitioned between water (20mL) and EtOAc (20 mL) and the aqueous layer was extracted with EtOAc(2×10 mL). The combined organic phases were dried over Na₂SO₄, filteredand concentrated in vacuo. The residue was purified by silica columnchromatography eluting with 2-5% MeOH/DCM to afford5-(5-amino-4-methyl-1-phenyl-1H-pyrazol-3-yl)-1-methylpyrimidin-2(1H)-one (23 mg, 50% yield) as a pale yellow gum. MS (apci)m/z=282.1 (M+H).

Step C: Preparation of1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(1-methyl-2-oxo-1,2-dihydropyrimidin-5-yl)-1-phenyl-1H-pyrazol-5-yl)urea

To a solution of 5-(5-amino-4-methyl-1-phenyl-1H-pyrazol-3-yl)-1-methylpyrimidin-2(1H)-one (23 mg, 0.08 mmol) in DCM (1 mL) was addedtriphosgene (12 mg, 0.04 mmol) and the mixture treated with DIEA (43 μL,0.24 mmol). The solution was stirred for 30 minutes at ambienttemperature then treated with(3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine[Preparation B3] (27 mg, 0.08 mmol) and DIEA (42 μL, 0.24 mmol) andstirring continued for 48 hours. The mixture was partitioned betweensaturated NH₄Cl (20 mL) and DCM (20 mL) and the aqueous layer extractedwith DCM (2×10 mL) plus methanol (1 mL). The combined organic phaseswere filtered, concentrated in vacuo and purified by silica columnchromatography eluting with 3-10% MeOH/DCM to afford the title compound(9 mg, 19% yield) as a pale yellow glass. MS (apci) m/z=564.2 (M+H).

Example 29

1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea Step A:Preparation of1,3-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one

5-Bromo-1,3-dimethylpyridin-1(1H)-one (1.0 g, 4.94 mmol),bis(pinnacolato)diboron (1.38 g, 5.44 mmol) and potassium acetate (1.46g, 14.8 mmol) were combined in dioxane (10 mL) in a sealed vessel andthe mixture was de-gassed with argon for 5 minutes. Palladium acetate(111 mg, 0.49 mmol) and XPHOS (354 mg, 0.74 mmol) were added, and themixture was degassed for an additional minute. The vessel was sealed andheated at 100° C. for 16 hours. The cooled mixture was filtered throughGF paper and the filtrate was concentrated. The residue was trituratedwith ether and filtered, and the filtrate was concentrated to afford1,3-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one(assume quantitative yield) as a tan solid. MS (apci) m/z=250.2 (M+H).

Step B: Preparation of5-(5-amino-4-methyl-1-phenyl-1H-pyrazol-3-yl)-1,3-dimethylpyridin-2(1H)-one

5-Amino-4-methyl-1-phenyl-1H-pyrazol-3-yl trifluoromethane sulfonate[Preparation E] (516 mg, 1.6 mmol),1,3-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one(600 mg, 2.41 mmol), K₂CO₃ (888 mg, 6.42 mmol) and Pd(PPh₃)₄ (185 mg,0.16 mmol) were combined in toluene (10 mL), water (5 mL) and EtOH (2.5mL) and warmed to 95° C. in a sealed vessel for 16 hours. The cooledmixture was filtered through GF paper and the filtrate was partitionedbetween water (50 mL) and EtOAc (50 mL). The aqueous layer was extractedwith EtOAc (2×30 mL) and the combined organic phases were washed withbrine (30 mL), dried over Na₂SO₄, filtered and concentrated. The residuewas purified by silica column chromatography eluting with 2% MeOH/DCM toafford5-(5-amino-4-methyl-1-phenyl-1H-pyrazol-3-yl)-1,3-dimethylpyridin-2(1H)-one(363 mg, 77% yield) as a dark pink foam. MS (apci) m/z=295.1 (M+H).

Step C: Preparation of1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea

To a solution of5-(5-amino-4-methyl-1-phenyl-1H-pyrazol-3-yl)-1,3-dimethylpyridin-2(1H)-one(45 mg, 0.15 mmol) in anhydrous DCM (2 mL) was added triphosgene (23 mg,0.08 mmol) followed by DIEA (79 μL, 0.46 mmol). The solution was stirredfor 30 minutes at ambient temperature and then treated with(3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine[Preparation B3] (50 mg, 0.15 mmol) and DIEA (79 μL, 0.46 mmol) andstirred for 16 hours. The mixture was partitioned between saturatedNH₄Cl (20 mL) and DCM (20 mL) and the aqueous layer was extracted withDCM (2×10 mL). The combined organic phases were washed with brine (10mL), dried over Na₂SO₄, filtered and concentrated. The residue waspurified by silica column chromatography eluting with 3-5% MeOH/DCM toafford the title compound (33 mg, 38% yield) as a colorless glass. MS(apci) m/z=577.3 (M+H).

Example 30

1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(methylsulfonyl)-1-phenyl-1H-pyrazol-5-yl)ureaStep A: Preparation of4-methyl-3-(methylsulfonyl)-1-phenyl-1H-pyrazol-5-amine

3-Bromo-4-methyl-1-phenyl-1H-pyrazol-5-amine [Preparation F] (300 mg,1.19 mmol), sodium methanesulfinate (486 mg, 4.76 mmol) and copperiodide (249 mg, 1.31 mmol) were combined in DMSO (5 mL) and purged withbubbling argon for 5 minutes. The mixture was stirred at 100° C. in asealed tube for 6 days, then the cooled mixture was partitioned betweenEtOAc (20 mL) and water (50 mL) containing a few drops of NH₄OH. Theaqueous layer was extracted with EtOAc (2×30 mL) and the combinedorganic phases were washed with water (5×20 mL) and brine (20 mL), thendried over Na₂SO₄, filtered and concentrated. The residue was purifiedby silica column chromatography eluting with hexanes/EtOAc (2:1) toafford 4-methyl-3-(methylsulfonyl)-1-phenyl-1H-pyrazol-5-amine (89 mg,30% yield) as a yellow, crystalline solid. MS (apci) m/z=252.1 (M+H).

Step B: Preparation of phenyl(4-methyl-3-(methylsulfonyl)-1-phenyl-1H-pyrazol-5-yl)carbamate

To a solution of 4-methyl-3-(methylsulfonyl)-1-phenyl-1H-pyrazol-5-amine(45 mg, 0.18 mmol) in EtOAc (2 mL) was added 2N NaOH (269 μL, 0.54 mmol)followed by phenyl chloroformate (45 μL, 0.36 mmol). The mixture wasstirred at ambient temperature for 16 hours, and then phenylchloroformate (75 μL) was added and the mixture stirred for 4 hours. Themixture was partitioned between water (10 mL) and EtOAc (10 mL) and theaqueous layer extracted with EtOAc (2×10 mL). The combined organicphases were washed with brine (10 mL), then dried over Na₂SO₄, filteredand concentrated to afford phenyl(4-methyl-3-(methylsulfonyl)-1-phenyl-1H-pyrazol-5-yl)carbamate (50 mg,75% yield) as a pale yellow foam. MS (apci) m/z=372.1 (M+H).

Step C: Preparation of1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(methylsulfonyl)-1-phenyl-1H-pyrazol-5-yl)urea

To a solution of(3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine[Preparation B3] (38 mg, 0.15 mmol) in anhydrous DCM (2 mL) was addedphenyl (4-methyl-3-(methylsulfonyl)-1-phenyl-1H-pyrazol-5-yl)carbamate(50 mg, 0.13 mmol) followed by DIEA (70 μL, 0.40 mmol). The mixture wasstirred at ambient temperature for 16 hours, then partitioned betweenwater (10 mL) and DCM (10 mL). The aqueous layer was extracted with DCM(2×10 mL) and the combined organic phases were washed with brine (10mL), dried over Na₂SO₄, filtered and concentrated. The residue waspurified by silica column chromatography eluting with 2% MeOH/DCM toafford the title compound (27 mg, 37% yield) as a white solid. MS (apci)m/z=534.2 (M+H).

Example 31

1-(3-acetyl-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)ureaStep A: Preparation of ethyl 3-cyano-2-oxobutanoate

To a solution of lithium bis(trimethylsilyl)amide (1.0 M in THF) (73.63mL, 73.63 mmol) and THF (75 mL) under N₂ at −78° C. was addedpropionitrile (6.304 mL, 88.35 mmol) dropwise over 2 minutes, and themixture was stirred for 1 hour. The mixture was then treated withdiethyl oxalate (10 mL, 73.63 mmol) dropwise over 5 minutes, stirred at−78° C. for 45 minutes, and then stirred at 0° C. for 1 hour. Themixture was diluted with H₂O (100 mL) and extracted with Et₂O (100 mL).The aqueous phase was adjusted to pH 5 with 6M HCl (13 mL) and thenextracted with Et₂O (3×100 mL). These organic extracts were washed withbrine (100 mL), dried over MgSO₄, filtered and concentrated to affordethyl 3-cyano-2-oxobutanoate (11.42 g, 99% yield) as a yellow-orangeoil.

Step B: Preparation of ethyl5-amino-4-methyl-1-phenyl-1H-pyrazole-3-carboxylate

To a solution of ethyl 3-cyano-2-oxobutanoate (11.42 g, 73.6 mmol) inEtOH (300 mL) was added phenylhydrazine (7.2 mL, 73.6 mmol) followed byhydrogen chloride (5-6 M in iPrOH) (14.7 mL, 73.6 mmol). The reactionmixture was stirred at reflux for 16 hours, then cooled and concentratedto 50 mL. The residue was diluted with saturated NaHCO₃ (150 mL) and H₂O(50 mL) and extracted with DCM (3×200 mL). The combined organic phaseswere dried over MgSO₄, filtered and concentrated. The residue waspurified by silica column chromatography eluting with 0-50%acetone/hexanes to afford ethyl5-amino-4-methyl-1-phenyl-1H-pyrazole-3-carboxylate (7.49 g, 49% yield)as an orange solid after drying in vacuo. MS (apci) m/z=246.1 (M+H).

Step C: Preparation of5-amino-4-methyl-1-phenyl-1H-pyrazole-3-carboxylic acid

To a solution of ethyl5-amino-4-methyl-1-phenyl-1H-pyrazole-3-carboxylate (3.0 g, 12.2 mmol)in THF (24 mL) and MeOH (12 mL) was added LiOH (2M aq) (13.5 mL, 27.0mmol) and the mixture was stirred at ambient temperature for 3 hours.The mixture was partially concentrated and then adjusted to pH 3 with 6MHCl (4.5 mL) and extracted with 10% MeOH/DCM (3×25 mL). The aqueousphase was further acidified with 6M HCl (1 mL) to pH 1, and thenextracted with 10% MeOH/DCM (3×25 mL). The aqueous phase was saturatedwith NaCl and extracted with 10% MeOH/DCM (3×25 mL). The combinedorganic extracts were washed with brine (50 mL), dried over MgSO₄,filtered and concentrated to afford5-amino-4-methyl-1-phenyl-1H-pyrazole-3-carboxylic acid (2.4 g, 90%yield) as a tan solid. MS (apci) m/z=218.1 (M+H).

Step D: Preparation of 5-amino-N-methoxy-N,4-dimethyl-1-phenyl-1H-pyrazole-3-carboxamide

To a solution of 5-amino-4-methyl-1-phenyl-1H-pyrazole-3-carboxylic acid(1.0 g, 4.6 mmol) in ACN (46 mL) were added N,O-dimethylhydroxylaminehydrochloride (539 mg, 5.5 mmol) and DIEA (2.4 mL, 13.8 mmol). Themixture was stirred until a solution formed and was then treated withHATU (2.1 g, 5.52 mmol) and stirred at ambient temperature for 90minutes. The reaction mixture was diluted with H₂O (50 mL) and extractedwith DCM (2×50 mL). The combined organic extracts were washed with brine(50 mL), dried over MgSO₄, filtered and concentrated. The residue waspurified by silica column chromatography eluting with 0-50% acetone inhexanes to afford5-amino-N-methoxy-N,4-dimethyl-1-phenyl-1H-pyrazole-3-carboxamide (550mg, 46% yield) as a peachy-tan solid. MS (apci) m/z=261.1 (M+H).

Step E: Preparation of1-(5-amino-4-methyl-1-phenyl-1H-pyrazol-3-yl)ethanone

A solution of5-amino-N-methoxy-N,4-dimethyl-1-phenyl-1H-pyrazole-3-carboxamide (365mg, 1.40 mmol) in DCM (15 mL) was cooled to 0° C. under N₂, and addedMeMgBr (3M in Et₂O) (491 μL, 1.47 mmol) was added dropwise, over 4minutes. The mixture was stirred at ambient temperature for 1 hour andthen treated with DCM (5 mL) and stirred for 90 minutes. The mixture wascooled to 0° C., and MeMgBr (0.3 mL) was added. The mixture was stirredat ambient temperature for 30 minutes, then cooled to 0° C. and treatedwith MeMgBr (0.4 mL). The mixture was stirred at ambient temperature for15 minutes. The reaction mixture was cooled to 0° C., quenched withsaturated NH₄Cl (25 mL), and extracted with DCM (3×25 mL). The combinedorganic extracts were dried over MgSO₄, filtered and concentrated. Theresidue was purified by silica column chromatography eluting with 0-50%acetone in hexanes to afford1-(5-amino-4-methyl-1-phenyl-1H-pyrazol-3-yl)ethanone (189 mg, 63%yield). MS (apci) m/z=216.1 (M+H).

Step F: Preparation of phenyl(3-acetyl-4-methyl-1-phenyl-1H-pyrazol-5-yl)carbamate

To a solution of 1-(5-amino-4-methyl-1-phenyl-1H-pyrazol-3-yl)ethanone(89 mg, 0.41 mmol) in EtOAc (4 mL) were added NaOH (0.41 mL, 2M, 0.83mmol) then phenylchloroformate (62 μL, 0.49 mmol). The mixture wasstirred at ambient temperature for 17 hours and then diluted with 10 mLEtOAc. The phases were separated, and the organic phase was washed withH₂O (20 mL) and brine (20 mL), then dried over MgSO₄, filtered andconcentrated. The residue was treated with hexanes (3 mL) and sonicated.The resulting solids were allowed to settle, the hexanes removed with apipette and the solids were dried in vacuo to afford phenyl(3-acetyl-4-methyl-1-phenyl-1H-pyrazol-5-yl)carbamate (133 mg, 99%yield) as pale yellow powder. MS (apci) m/z=336.1 (M+H).

Step G: Preparation of1-(3-acetyl-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea

A solution of(3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-amine[Preparation B3] (105.8 mg, 0.41 mmol) in iPrOH (2 mL) was added tophenyl (3-acetyl-4-methyl-1-phenyl-1H-pyrazol-5-yl)carbamate (133 mg,0.40 mmol). The mixture was stirred at reflux for 10 minutes and thenallowed to cool slowly to ambient temperature over 16 hours. The mixturewas diluted with iPrOH (0.5 mL), then filtered, washed with iPrOH (2×0.5mL) and Et₂O (3×1 mL) and dried in vacuo to afford the title product(113 mg, 57% yield) as an off-white solid. MS (apci) m/z=498.2 (M+H).

1. A method for treating a disease or disorder selected from pain andcancer, in a mammal in need thereof, which comprises administering tosaid mammal a therapeutically effective amount of a compound of FormulaI compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein: Ring B and theNH—C(═X)—NH moiety are in the trans configuration; R^(a), R^(b), R^(c)and R^(d) are H; X is O; R¹ is (1-3C alkoxy)(1-6C)alkyl; R² is H; Ring Bis Ar¹; Ar¹ is phenyl optionally substituted with one or moresubstituents independently selected from halogen; Ring C is

R³ is Ar²; Ar² is phenyl optionally substituted with one or moresubstituents independently selected from halogen; R⁴ is selected from(1-6C alkyl)SO₂—, (1-6C alkyl)C(═O)— and from the structures:

R^(m) is (1-3C)alkyl substituted with 1-3 fluoros, or (3-4C)cycloalkyl;R^(n) is (1-3C)alkyl; R^(q) is (1-3C)alkyl optionally substituted with1-3 fluoros; R^(x) is (1-6C)alkyl, halogen, CN, hydroxy(1-6C)alkyl,trifluoro(1-6C)alkyl, (3-6C)cycloalkyl, (3-6C cycloalkyl)CH₂—, (3-6Ccycloalkyl)C(═O)—, (1-3C alkoxy)(1-6C)alkyl, (1-6C)alkoxy,(1-6C)alkylsulfonyl, NH₂, (1-6C alkyl)amino, di(1-6C alkyl)amino,trifluoro(1-3C)alkoxy or trifluoro(1-6C)alkyl; n is 0, 1, 2, 3 or 4; mis 0, 1, 2 or 3; R^(y) is F or (1-3C)alkyl optionally substituted with1-3 fluoros; p is 0, 1 or 2; R^(z) is (3-4C)cycloalkyl, or (1-3C)alkyloptionally substituted with 1-3 fluoros; and R⁵ is (1-6C)alkyl.
 2. Themethod according to claim 1, wherein R⁴ is selected from the structures:


3. The method according to claim 1, wherein R⁴ is selected from thestructures:


4. The method according to claim 3, wherein R⁴ is selected from thestructures:


5. The method according to claim 1, wherein R⁴ is selected from thestructures:


6. The method according to claim 5, wherein n is 0 or 1 and m is 0 or 1.7. The method according to claim 6, wherein R⁴ is selected from thestructures:


8. The method according to claim 1, wherein Ring B and the —NH—C(═X)—NH—moiety of Formula I are trans in the absolute configuration shown instructure C:


9. The method according to claim 1, wherein Ring B and the —NH—C(═X)—NH—moiety of Formula I are trans in the absolute configuration shown instructure D:


10. The method of claim 1, wherein said compound is selected from:1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(6-methylpyridin-3-yl)-1-phenyl-1H-pyrazol-5-yl)urea;1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(2-fluoropyridin-3-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea;1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyridin-3-yl)-1-phenyl-1H-pyrazol-5-yl)urea;1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(5-methylpyridin-3-yl)-1-phenyl-1H-pyrazol-5-yl)urea;1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(5-methoxypyridin-3-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea;1-(3-(5-cyanopyridin-3-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea;1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(6-methoxypyridin-3-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea;1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(2-ethoxypyrimidin-5-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea;1-(3-(2-cyclopropylpyrimidin-5-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea;1-(3-(2-cyclopropylpyrimidin-5-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea;1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(2-methoxypyrimidin-5-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea;1-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1H-pyrazol-5-yl)urea;1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1H-pyrazol-5-yl)urea;1-(3-(2-ethoxypyrimidin-5-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea;1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(2-ethoxypyrimidin-5-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea;1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-1-phenyl-1H-pyrazol-5-yl)urea;1-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-1-phenyl-1H-pyrazol-5-yl)urea;1-((3S,4R)-4-(3,5-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-1-phenyl-1H-pyrazol-5-yl)urea;1-(3-(2-(cyclopropylamino)pyrimidin-5-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea;1-(3-(2-(cyclopropylamino)pyrimidin-5-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea;1-(trans-4-(3-chloro-4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-phenyl-1H-pyrazol-5-yl)urea;1-(trans-4-(4-chloro-3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-phenyl-1H-pyrazol-5-yl)urea;1-(trans-4-(3-chloro-5-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-phenyl-1H-pyrazol-5-yl)urea;1-(trans-4-(3-chlorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-phenyl-1H-pyrazol-5-yl)urea;1-((3S,4R)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-yl)-3-(4-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-phenyl-1H-pyrazol-5-yl)urea;1-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-phenyl-1H-pyrazol-5-yl)urea;1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(1-methyl-2-oxo-1,2-dihydropyrimidin-5-yl)-1-phenyl-1H-pyrazol-5-yl)urea;1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea;1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(methylsulfonyl)-1-phenyl-1H-pyrazol-5-yl)urea;1-(3-acetyl-4-methyl-1-phenyl-1H-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)urea;and pharmaceutically acceptable salts thereof.
 11. The method of claim1, wherein the method is a method for treating pain.
 12. The method ofclaim 11, wherein said pain is chronic pain.
 13. The method of claim 11,wherein said pain is acute pain.
 14. The method of claim 11, whereinsaid pain is selected from inflammatory pain, neuropathic pain, painassociated with cancer, pain associated with surgery, and painassociated with bone fracture.
 15. The method of claim 1, wherein saidcancer is a cancer having a dysregulation of TrkA.
 16. The method ofclaim 15, wherein said cancer is selected from non-small cell lungcancer, papillary thyroid carcinoma, glioblastoma multiforme, acutemyeloid leukemia, acute myeloid leukemia, colorectal carcinoma, largecell neuroendocrine carcinoma, prostate cancer, neuroblastoma,pancreatic carcinoma, melanoma, head and neck squamous cell carcinomaand gastric carcinoma.
 17. The method of claim 10, wherein the method isa method for treating pain.
 18. The method of claim 17, wherein saidpain is chronic pain.
 19. The method of claim 17, wherein said pain isacute pain.
 20. The method of claim 17, wherein said pain is selectedfrom inflammatory pain, neuropathic pain, pain associated with cancer,pain associated with surgery, and pain associated with bone fracture.21. The method of claim 10, wherein said cancer is a cancer having adysregulation of TrkA.
 22. The method of claim 21, wherein said canceris selected from non-small cell lung cancer, papillary thyroidcarcinoma, glioblastoma multiforme, acute myeloid leukemia, acutemyeloid leukemia, colorectal carcinoma, large cell neuroendocrinecarcinoma, prostate cancer, neuroblastoma, pancreatic carcinoma,melanoma, head and neck squamous cell carcinoma and gastric carcinoma.